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GENERAL SUMMARY 
 
 
 Schistosome parasites need to adapt to survive at various points of their 
complex life cycle. In the vertebrate definitive host, this involves the avoidance 
of the host immune system in general and the battle against the host 
complement system participating in the first line of immune defenses against 
the invading parasite in particular. There are several complement regulators 
found on schistosomes. We are interested in complement regulation at the 
level of the formation of the C3 convertase by a complement C2 binding 
receptor. This C2 binding receptor was first characterised in one of the  
human schistosoma species S. haematobium and denominated ShTOR for 
trispanning orphan receptor. After the S. mansoni genome had been 
sequenced, we had a closer look at the ShTOR receptor homologue in this 
species.  
 
The aims of the project were:  
 
1.  To characterise the S. haematobium TOR receptor homologue 
SmTOR in S. mansoni (PART I)  
 
2.  To test if the first extracellular domain 1 of SmTOR binds C2 
and to define its antigenicity (PART II)  
 
3.  To define the immunogenicity of SmTORed1 in mice and test 
it as a vaccine candidate against schistosomiasis in a murine 
vaccination and challenge model (PART III) 
 
In line with the structure of the project outline presented above, the work 
presented in this thesis can be summarised as follows:  
 
 1.  We found that SmTOR is a tetraspanning receptor expressed in the 
tegumental membranes of schistsosomes. As compared to the truncated 
receptor versions described before, it possesses a longer extracellular   
domain 1 still comprising the C2 binding motif. Its expression was highest in 
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the infectious stage of the parasite, in the S. mansoni cercariae. SmTOR 
might play an important role in skin penetration of S. mansoni larvae and it is 
an interesting target for vaccination since it is an early antigen on schistosoma 
cercariae and has a complement inhibitory activity.   
 
 2. We overexpressed SmTOR extracellular domain 1 (rSmTORed1) in  
E. coli, which was purified by immobilised metal affinity chromatography. We 
were able to show that full length recombinant SmTORed1 binds C2. We 
moreover detected specific antibodies against rSmTORed1 in sera of patients 
infected with S. mansoni and also in some normal human sera. Specificity of 
antibody to rSmTORed1 was ensured by pre-incubation of sera with the 
Halo-tagged version of SmTORed1 immobilised on a solid support.  
SmTORed1 N-terminally fused to HaloTag and the corresponding control 
constructs were produced in E. coli as well.  
 
 3. We tested the immunogenicity of rSmTORed1 in two different mouse 
strains, BALB/c and C57BL/6 using as adjuvants muramyl dipeptide (MDP) 
and Complete/Incomplete Freund’s adjuvant (CFA/IFA). BALB/c mice 
immunised with rSmTORed1 in CFA/IFA generated the highest titer of specific 
antibodies to rSmTORed1 and were subsequently tested in an immunisation 
challenge experimental setup. For this, immunised mice were infected with 
S. mansoni cercariae and status of infection assessed by adult worm count. 
Immunised mice showed a 60 % reduction of worm burden when compared to 
the two control groups.   
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GENERAL INTRODUCTION 
 
 Helminths are multicellular eukaryotic parasites that are able to 
ensconce themselves in the human host for decades (1). Parasitic helminth 
infections account for disability and morbidity amongst the 1.2 billion people 
affected by these type of neglected tropical diseases (NTDs) (2). In fact, 
NTDs seem to not only be neglected by the majority of people not at risk due 
to their privileged economic status, but rather forgotten besides high mortality 
diseases such as HIV/AIDS, malaria and tuberculosis. NTDs primarily do 
affect the population of developing countries, where they have a non-
negligible impact on child development, pregnancy outcome, worker 
productivity and malaria and HIV/AIDS co-infections (3). NTDs include chronic 
parasitic and bacterial infections. Schistosomes are parasitic helminths 
belonging to the phylum of platyhelminths (4). They were first discovered by 
Theodor Bilharz in 1815 (5), but must have infected their human hosts during 
thousands of years, as calcified eggs had been discovered already in 
mummies (6). Their persistent existence over thousands of years might be 
one of the reasons, why during co-evolution with their human host, 
schistosomes developed into well-adopted parasites very well capable to 
escape the host immune response and to settle down in such an unfriendly 
environment as the human venous system. Schistosomiasis affects more than 
207 million people worldwide with an estimated number of 700 million people 
at risk in 74 endemic countries (7). Although the infection can be treated by 
using chemotherapeutics, it is hardly possible to influence strongly the risk of 
re-infection due to the fact that it is difficult to control the frequency of 
cercariae in contaminated waterbodies (8). 
 
Life Cycle of Schistosomes 
 
 The infectious stage of Schistosoma, the so called cercariae, rest more 
or less transiently in a fresh-water environment depending on the strain and 
are only prompted to move in response to certain stimuli (9). These 
presumably include the light shade play and water turbulence, as well as 
chemical cues and a thermostatic gradient that cercariae are responding 
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to (10). Medium-chain free fatty acids such as linoleic acid in the human skin 
act as signal for skin invasion and the cercariae start to secrete gland 
contents from the acetabular gland complex (11). The post-acetabular glands 
facilitate the attachement of the cercariae to the skin surface by releasing a 
mucous-like substance (12). In addition to the acetabular glands, the head 
gland and the sub-tegumental cell bodies play a role in the process of host 
invasion and subsequent parasite transformation, that is the transformation of 
cercariae into schistosomulae (10). The outermost layer of the skin though, 
the stratum corneum, represents no real barrier to the cercariae as in a 
hydrated environment the lipid lipid interactions are lost. Gland secretions 
containing cercarial proteases help to degrade the desmosome-linked cells of 
the stratum spinosum, the basement membrane contents and the subjacent 
dermal layers (11, 13). Schistosome cercariae infecting humans penetrate 
wrinkles, smooth skin and hair follicles with 60 percent of them still having the 
tails attached to the cercarial bodies (14). Transformation of cercariae into 
schistosomulae involves loss of the cercarial bifurcated tails, shedding of the 
glycocalyx and the re-organisation of the trilaminate surface membrane into a 
heptalaminate membrane (12). Few infective larvae are capable of reaching 
the dermis of human skin within 10 minutes (15), but the majority of the 
transformed schistosomulae that do not die during skin penetration reach the 
dermis within 48 hours (9). After migration through the extracellular dermis, 
schistosomulae enter the vascular space via a small venule or a lymphatic 
vessel and make their way to the lungs. They further migrate in the blood to 
the portal venous system. Schistosomulae mature in the portal vein for 4 - 6 
weeks whereon females mate with their male counterpart in order to form the 
typical worm pairs (8). The longer thinner female is held in a groove of the 
male's body. As such, they migrate to superior mesenteric veins (S. mansoni), 
the inferior mesenteric and superior hemorrhoidal veins (S. japonicum) or the 
vesical plexus and the veins draining the ureters (in the case of                     
S. haematobium) (16). The female starts to produce hundreds and thousands 
of eggs that penetrate the surrounding tissues and end up in the intestine or 
the bladder. Eggs are excreted in the urine or feces and the ciliated 
miracidium larvae hatch when the eggs are in contact with water. The 
miracidiae thereafter infect the intermediate host, specific freshwater snails of 
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the Biomphalaria (S. mansoni), Bulinus (S. haematobium) or Oncomelania 
genus (S. japonicum) and undergo asexual reproduction that generates 
mother and then daughter sporocysts. The daughter sporocysts give rise to 
cercariae that are released into the water. With this step, the schistosomes 
complete their life cycle.  
 
Immunopathology 
 
 The pathology of schistosomiasis is manifesting in two different phases 
of the disease, in the acute phase and during the chronic phase.  
 Skin reactions at the site of penetration by the cercariae develop within a 
few hours after infection and especially after primary infections. The dermatitis 
is similar to the so-called swimmer's itch that occurs in sensitised persons 
infected with animal trematodes (17).   
 Acute schistosomiasis is a febrile illness occuring a few weeks to months 
after infections and is also referred to as Katayama fever (8). Symptoms at 
initial presentation include myalgia, headache, cough, abdominal pain and 
fever (18). Patients typically suffer from eosinophilia due to a systemic 
hypersensitivity reaction to antigens appearing visible to the host immune 
system at the time point of oviposition.  
 Chronic schistosomiasis is caused by the schistosome eggs that get 
trapped in the host tissue during perivesical or periintestinal migration. It  
is characterised by formation of granulomatous lesions at the site of  
egg accumulation resulting in hepatic and intestinal schistosomiasis, urinary 
disease or ectopic schistosomiasis such as pulmonary, genital and neuro-
schistosomiasis (8). 
 Gastrointestinal and liver disease cause persinusoidal inflammation in 
the liver and hyperplasia, ulceration, microabcess formation and polyposis in 
the gut wall in line with the granulomatous inflammatory response due to eggs 
in the liver (S. mansoni and S. japonicum) and the genitourinary tract           
(S. haematobium). More severe pathology such as occlusion of the portal 
veins, portal hypertension and gastrointestinal bleeding develops in the 
course of fibrotic or chronic hepatic schistosomiasis (8). Excess of 
extracellular matrix deposited in periovular granuloma and periportal fibrosis 
 8	
  
are the two main presentations of fibrosis in hepatic schisotomiasis. Life 
threatening conditions involve the emergence of portal hypertension as a 
consequence of the altered vascular architecture of the liver, splenomegaly 
and porto-systemic collateral circulation and subsequently the rupture of 
oesophageal varices where the host dyes of acute anemia (19).  
 Urinary schistosomiasis is caused in response to infection with              
S. haematobium. Symptoms include dysuria and hematuria, later on 
proteinuria and disease progression is accompanied with calcifications in the 
bladder and obstruction of the ureter (16). There is evidence of environmental 
factors promoting bladder cancer association infection including 
schistosomiasis as a major risk factor (20).  
 
Host Parasite Interactions 
 
 Schistosomes at various stages in their life cycle have to defend 
themselves either against attack by the innate or adaptive immune system.  
When schistosome larvae penetrate the human skin, they coat themselves in 
blood group antigens supposably as a protective measure (21). Cercariae in 
contrast to schistosomulae are susceptible to complement attack and 
activation of complement was dependent on the alternative pathway but 
independent of antibody. Cercariae loose their glycocalyx and their tail when 
transforming into schistosomulae, which renders them less susceptible to 
complement attack (22). On the other hand, schistosomulae are vulnerable to 
oxidative stress generated by host phagocytes (23). Adult worms however 
have the capacity for oxidant detoxification due to the higher level of 
antioxidant enzymes and glutathione within their tegument and gut epithelium 
(24, 25).  
 Other than defending themselves against host immunity parasites are 
also capable circumventing damage and counterattack the host by 
immunomodulation. For example cercariae might inhibit T-cell activation by 
blocking potassium channel activity (26), interfere with TLR signaling (27) or 
modify dermal immunity by secreting sperm coat domain proteins that have 
similarities with host chemokines (19, 24). S. mansoni egg translocation from 
the portal capillaries to the gut lumen depends on the  host immune response 
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(28), female worms produce eggs in a host TNF dependent manner (29) and 
adult worm growth and development might depend on host TGFβ (30).   
 One other important aspect beside the worm's attack and defense 
strategies is the subversion of immune attack on the parasite surface. There 
are antibodies and complement factors on the adult parasite surface (31-33) 
and complement factors are found in the human skin after invasion of 
cercariae (34), which suggests there might be a fight going on against the 
human complement system at the host parasite interface.   
   
The Complement System 
 
 Adult parasites are constantly facing attack by the complement, a 
system of more than 30 glycoproteins in plasma and on cell membranes that 
form a proteolytic cascade once activated by one of the three possible ways; 
the classical pathway (CP), alternative pathway (AP) or mannose-binding 
lectin pathway (MBL-P) of complement activation (16). All three pathways 
converge at the level of the C3 convertase formation and subsequent 
proteolytic cleavages lead to the formation of a membrane attack complex 
C5b-C9 leading to the direct killing of pathogens. Elimination of pathogens is 
also triggered by the generation of covalently bound cleavage products of C3 
and C4 in a process called opsonisation, marking pathogens for recognition 
by macrophages and neutrophils thereby facilitating their phagocytosis (35). 
Furthermore, complement plays a bridging function in linking the innate and 
adaptive immune system by instructing and stimulating the acquired immune 
response (36).  
 CP is initiated by the binding of C1q to IgG or IgM bearing immune 
complexes or to a variety of ligands such as a C-reactive protein, pentraxin 
and a variety of structurally different target molecules including parasites (37). 
An activation signal is then transmitted to C1s-C1r-C1r-C1s tetramer 
assembled of two serine proteases C1r and C1s (38), more precisely to C1r 
that undergoes autoactivation and cleaves C1s. Activated C1s cleaves C4 
into C4b and C4a and then C2 bound to C4b generating the C4bC2a enzyme 
complex, the C3 convertase of the CP (39).  
 MBL-P is activated in an analogous way, when MBL or ficolins in 
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complex with their serine proteases MASP-1/MASP-2 get activated by binding 
to carbohydrates on microorganisms and auto-activated MASP-2 so cleaves 
its downstream targets C4 and C2. 
 The AP of complement is initiated when C3 gets activated to form 
C3(H2O) with a internal thioester of C3 hydrolysed by water in a so-called tick-
over process (40). C3(H2O) has an altered conformation that allows the 
binding of factor B (FB), its cleavage and the formation of the fluid phase AP 
convertase C3(H2O)Bb (41). Formation of AP convertase bound to cell 
surface macromolecules happens when activated C3b with its fully exposed 
thioester is generated in an unknown process (42, 43). This thioester bond is 
displaced by nucleophilic attack by an amine or hydroxyl group on the 
pathogen surface thereby covalently attaching C3b to its surface (43). Bound 
C3b allows the binding of FB that undergoes a conformational change 
rendering it susceptible for cleavage by factor D (FD). FD cleavage of C3b 
bound FB generates the AP C3 convertase C3bBb.  
 The complement system is regulated in a tight way by membrane-bound 
and soluble complement regulators (all reviewed in (44)). The list of 
membrane-bound complement regulators comprise complement receptor 1 
(CR1, CD35), decay-accelarating factor (DAF, CD55), membrane cofactor 
protein (MCP, CD46) and protectin (CD59). Fluid-phase complement 
regulators can be grouped according to their point of action: One group 
consisting of factor H (FH), factor H like protein 1 (FHL1) and properdin 
regulate the AP. Regulators of the CP and MBL pathways are C4b binding 
protein (C4BP) and C1 inhibitor (C1INH). Complement factor H related 
protein 1 (CFHR1), clusterin and vitronectin all interfere with the terminal 
pathway of the complement cascade.  
 CR1, DAF and MCP all act as decay accelerating factors of C3 and C5 
convertases. In addition, CR1 and MCP are cofactors for the serum    
protease I, which degrades C3b and C4b to fragments that are no more 
functional. CD59 regulates inhibits terminal complement complex formation.  
 C1INH is a serine protease inhibitor targeting C1r, C1s and MASP2. FH, 
FHL and C4BP act on the AP or CP C3 convertase decay and all of them as 
cofactor for FI. Properdin stabilises the AP convertases. CFHR1 inhibits the 
C5 convertase and membrane attack complex formation. Clusterin and 
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vitronectin as well prevent MAC insertion into the membrane.   
 
Schistosomes and Complement 
 
 It is likely, that all three pathways of complement activation are activated 
on the schistosome surface (45): multiple isoforms of IgG and IgM and IgA 
have been detected on the adult tegument (46, 47) and MBL pathway was 
observed to be activated in vitro (48). Worms and schistosomes that are 
insensitive against complement attack got vulnerable after trypsin treatment 
(49, 50). This suggests the existence of complement regulatory molecules on 
the parasite as a defense mechanism.  
 Paramyosin (a homologue of human CD59) has been assigned with a 
multiple role in complement regulation on the surface of schistosomes. An   
Fc receptor has been postulated to be at the parasite surface (51) that 
captures host IgG while loosen its capacity to activate complement. At the 
same time, the receptor has been suggested to function as C1INH (52) and 
blocking the complement cascade at a late stage by binding complement C8 
and C9 (53, 54). However, there is a debate about paramyosin even being 
present or not on the schistosome surface (45).  
 A C3 receptor has been characterised on the S. mansoni tegument 
regulating all arms of the complement system (55) and adult schistosomes 
and schistosomulae somehow are capable of acquiring GPI-anchored host 
DAF (56, 57).   
 We were interested in a C2 receptor highest expressed on the tegument 
of complement-sensitive S. mansoni cercariae (58), interfering with the 
formation of the C3 convertase (59, 60).  
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PART I: Schistosoma mansoni TOR is a tetraspanning orphan receptor 
on the parasite surface 
 
Manuscript published in: Parasitology (2009), 136(5), 487-498  
 
ABSTRACT 
 
A trispanning orphan receptor (TOR) has been described in 
Schistosoma haematobium and S. mansoni. Here we report the complete 
molecular organisation of the S. mansoni TOR gene, also known as SmCRIT 
(complement C2 receptor inhibitor trispanning). The SmTOR gene consists of 
four exons and three introns as shown by cloning the single exons from               
S. mansoni genomic DNA and the corresponding cDNA from the larval stage 
(cercaria) and the adult worm. The SmTOR ORF consists of 1260 bp and is 
longer than previously reported, with a fourth trans-membrane domain 
(proposed new name: Tetraspanning Orphan Receptor), and with, however, 
an unchanged C2-binding domain on the extracellular domain 1 (ed1). This 
domain differs in S. japonicum. A protein at the approximate expected 
molecular weight (55 kDa) was detected in adult worm extracts with polyclonal 
and monoclonal antibodies, and found to be expressed on the tegumental 
surface of cercariae.  
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INTRODUCTION 
 
Schistosomiasis is a parasitic infection also known as bilharzia named 
after Theodor Bilharz who first described it (1). There are five species of 
schistosoma that are known to infect humans by contact with its larval  
stage, the cercariae: Schistosoma mekongi, S. intercalatum, S. mansoni,  
S. japonicum and S. haematobium, the latter three being the main 
schistosome species that affect humans (2). Adult worm pairs reside in host 
veins and produce eggs which penetrate the tissue. They end up excreted 
with feces where they complete the schistosoma life cycle by hatching and re-
infecting fresh-water snails as intermediate hosts (1). Between the mid-1990s 
and 2003 the estimated number of people at risk from schistosomiasis 
increased from 702 million to 779 million and the estimated number of 
individuals infected increased from 193 millions to 207 million (3). The 
treatment of choice is the chemotherapeutic agent praziquantel. However, 
drug treatment alone might not be sufficient and a vaccine-linked 
chemotherapy to control schisotomiasis is recommended (4). Naturally 
acquired immunity or vaccination in animals strongly diminishes the pathology 
associated with schistosome infection. There are efforts to develop a vaccine 
against schistosomiasis. Radiation-attenuated cercariae induced a high level 
of protection in animal models (5, 6) and naturally resistant population groups 
exist (7, 8), which suggest that development of an effective vaccine is likely to 
be possible (9). There is a list of recombinant proteins that correlate with 
resistance in human studies and/or have shown efficacy in animal models (9). 
Among these promising vaccine candidates are the tetraspanins SmTSP-1 
and SmTSP-2, that are both recognised by IgG1 and IgG3 from putatively 
resistant individuals, SmTSP-2 providing high level of protection in the mouse 
vaccination model in addition (10). Another candidate, Fatty Acid-Binding 
Protein (FABP)-Sm14 is at the stage of planned clinical trials after scale-up 
and industrial production processes have been put in place (11). 
The host complement system participates in the first line of immune 
defenses against the invading parasite. Of the three pathways of complement 
activation, the alternative pathway was shown to attack schistosomula (12, 
13) and S. mansoni adult worms (14, 15). Schistosomes are sensitive to 
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killing by complement, but lose their sensitivity with loss of the glycocalyx and 
maturation. Partial tryptic digestion of adult worm tegumental proteins 
rendered them sensitive to complement attack as shown for S. mansoni by 
Fishelson’s group (16). The mannose binding lectin pathway has also been 
shown to be activated (17), but there has been no consensus regarding the 
activation of the classical pathway. Some researchers find IgG (different 
subtypes) and IgM deposits at the parasite surface and some do not (18-20). 
Identification of host IgG1, IgG3, IgM, C3 degradation products (21)  and C4 
(22), but no known proteins with homology to Fc receptors by proteomic 
analysis of the adult worm tegument, provide a strong argument for the 
activation of classical pathway (22). In addition, there have been reports of 
complement regulators being present on schistosomes including C1q binding 
proteins, surface C3 receptor, host acquired DAF and SCIP-1/paramyosin 
(23), which might regulate the terminal membrane attack complex insertion, 
although this remains a matter of debate (24).  
A specific surface receptor for C2, the Schistosoma trispanning orphan 
receptor (TOR) was described by Inal some time ago (25). In S. haematobium 
and S. mansoni TOR was found to be a 32 kDa trans-membrane protein 
located at the tegumental surface of adult worms and was also expressed in 
the larval stage (cercaria). Inal showed that a short amino acid sequence of 
the ShTOR extracellular domain 1 (ed1) binds C2 resulting in a competitive 
inhibition of the binding of C2 to C4b. In addition it inhibits the cleavage of C2 
by C1s. Further experiments indicated that this sequence was a strong 
inhibitor of classical pathway activation. This sequence, corresponding to the 
C-terminal 11 amino acids of ed1 (termed H17 peptide), has homologies with 
a specific sequence of the beta chain of C4, which may explain the 
competitive binding between H17 and C4 for C2 (26, 27). Hui et al. (28) 
defined more precisely the binding site of H17 to be the vWFA domain of C2. 
Therefore, TOR was renamed CRIT for “complement C2 receptor inhibitor 
trispanning” (29, 30). Recently, H17 was shown to interfere also with the 
formation of the alternative pathway C3 convertase by binding to FB (28, 31). 
Evidently, TOR might be a central element for schistosomes to escape innate 
immunity. 
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Here we report the exon/intron structure of the SmTOR gene. Four 
exons were amplified and sequenced from S. mansoni genomic DNA based 
on database analysis of the S. mansoni genome and comparing it with 
S. japonicum TOR (SjTOR) cDNA. The full-length construct was amplified 
from the adult worm and cercaria cDNA preparations. Further evidence for 
expression of the TOR protein was gained by Western blotting with 
S. mansoni proteins and probing these with antibodies directed against  
parts of its extracellular domains. Based on these results we propose a new 
structure of SmTOR/CRIT.  
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MATERIALS AND METHODS  
 
Alignment of Schistosoma japonicum cDNA with Schistosoma mansoni 
genome: derivation of SmTOR exon/intron gene organisation 
 
 SjTOR cDNA (PubMed accession number AY814912; http:// 
www.ncbi.nlm.nih.gov/) was aligned with S. mansoni GeneDB database  
entry Smp_093840 (http://www.genedb.org/genedb/smansoni/) designated  
as a putative trispanning orphan receptor gene. The resulting overlapping 
sequences served as a basis to define SmTOR exon/intron boundaries.  
 
PCR amplification and sequencing of SmTOR fragments from S. mansoni 
genomic DNA  
 
S. mansoni genomic DNA was prepared from cercariae-infected water. 
Cercariae in suspension were washed by pelleting 5 min at 3000 rpm and 
resuspending in 1 x PBS and an additional centrifugation step as before. The 
pellet was resuspended in 1 x TE (Fluka 86377)/100 mM NaCl and snap 
frozen in liquid nitrogen. After thawing, 20 % SDS (Fluka 05030) and 
Proteinase K (Fluka 82456) were added to final concentration of 1 % and        
1 mg/ml respectively. The mixture was incubated at 60 °C over night. One 
volume of TE saturated phenol/chloroform was added to the sample and 
mixed by inversion for 15 min. After spinning at full speed in a microfuge, the 
aqueous supernatant was transferred to a new tube and the extraction step 
repeated twice, but using chloroform only in the cycle. DNA in the aqueous 
phase was then precipitated by adding 1/10 v/v NaOAc pH 5.5 overlaid with 
2.5 volumes of ethanol and incubating at -20 °C over night. DNA was pelleted 
at full speed, air-dried and resuspended in 1 x TE. Primers (Microsynth) 
flanking the putative SmTOR exons were designed according to the 
exon/intron map (Table 1). PCR was performed with Taq PCR core kit 
(Quiagen) using 0.75 mM specific primers and 30 ng S. mansoni genomic 
DNA as template. The PCR program was 95 °C for 5 min, then 35 cycles of 
95 °C for 45 s, 59 °C for 1 min, 72 °C for 1 min followed by a final extension 
step of 72 °C for 15 min. Reaction products were separated by 1% agarose 
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gel electrophoresis, excised bands were purified (QIAquick® PCR purification 
kit) and cloned into a TOPO vector (Invitrogen) for sequencing. Blanks for 
each PCR reaction using water only were negative (not shown). All PCR 
products were sequenced in both directions, using plasmid preparations from 
three different clones respectively. 
 
Table 1. Primer list used for amplification of single exons of SmTOR and 
amplifications from cDNA. Expected fragment lengths are indicated for primer 
pairs used to amplify single exons. Numbers used in the primer names 
indicate its 5’ annealing position within the exon or the flanking intron, 
preceded by a positive or negative sign respectively, if not annealing at the 
ends of the exons of interest due to issues of melting temperature when 
designing.  
 
 
 
RNA isolation from S. mansoni adult worms or cercariae and full length cDNA 
preparation   
 
S. mansoni RNA was isolated from adult worm preparations of               
S. mansoni (Liberian strain, kindly donated by Dr. J. Chollet, STI Basel) 
isolated from NMRI mice or cercariae. Worm pairs were briefly rinsed with 1 x 
PBS and preserved in RNAlater® reagent (Ambion). Worm tissue or cercariae 
were homogenised by mechanical disruption with Molecular Grinding ResinTM 
(G-Biosciences) resuspended in lysis buffer RLT (AllPrepTM DNA/RNA/Protein 
extraction kit, Quiagen). After removal of resin and cell debris by 
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centrifugation at 10 000 rpm, for 5 min at 4 °C, the homogenate was applied 
on a Quiagen AllPrep column and RNA extracted according to the 
manufacturers protocol.  
 
 RT-PCR and cDNA alignment SmTOR/SjTOR 
 
Single strand cDNA synthesis was performed using random hexamers, 
oligo dT primers or gene specific primer SmTOR_exon4_rev (Table 1). 50 ng 
of RNA was reverse transcribed per reaction with SuperScriptTM III First-
Strand Synthesis System for RT-PCR (Invitrogen). Using the transcribed 
single stranded cDNAs as a template, the SmTOR transcribed sequence  
was amplified with gene specific primer pair SmTOR_ex1_-15_fwd  
and SmTOR_exon4_rev (Table 1) using the same cycling conditions 
described above. Reaction mixtures were run on a 1% agarose gel  
and the single bands purified, cloned and analysed as described above. 
SmTOR ORF on sequenced cDNA was aligned with SjTOR ORF on  
cDNA entry (AY814912) using EMBOSS pairwise alignment algorithm 
(http://www.ebi.ac.uk/emboss/align/). 
 
Real-time quantitative PCR analysis (qPCR) 
 
Total RNA was isolated from S. mansoni cercaria, schistosomula, adult 
worm pairs, eggs and miracidia as described above. Eggs and miracidia were 
isolated as reported before (32). Schistosomula were generated by in vitro 
transformation (33). cDNA was generated as described above and 1 ml per 
reaction was used performing qPCR on a ABI 7900 (Applied Biosystems) 
instrument using SYBR® green as a fluorescence dye (Power SYBR® Green 
PCR Master Mix, Applied Biosystems). Primers targeting a 219 bp region  
of the constitutively expressed SmTPI (triose phosphate isomerase)  
(34) and primers for used for SmTOR (SmTOR_ex1_-15_fwd and 
SmTOR_ex2_+33_rev) are listed in Table 1. Amplification of contaminating 
genomic DNA was avoided by using sets of primers located in different exons. 
Results were evaluated using the 2-∆∆CT method (35). 
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Protein sequence alignment S. japonicum and S. mansoni TOR and 
secondary structure prediction of SmTOR 
 
Molecular weight analysis was performed using the EMBOSS Pepstats 
program at the European Bioinformatics Institute web site (http:// 
www.ebi.ac.uk/emboss/pepinfo). Proteins were aligned using EMBOSS 
pairwise alignment algorithm (http://www.ebi.ac.uk/emboss/align/). TopPred 
was used for transmembrane prediction analysis (36) using upper cutoff 
hydrophobicity values. Secondary structure prediction analysis was performed 
using PSIPREDView (37, 38). The signal sequence prediction was performed 
using SignalP 3.0 server (http://cbs.dtu.dk/services/SignalP).  
 
Adult worm tegument membrane preparations and Western blot analysis 
 
Tegument surface membranes of S. mansoni adult worms were 
prepared as done before applying freeze thaw method followed by vortex 
pulses in order to strip the parasites (39, 40). Samples were run on a standard  
12% SDS PAGE acrylamide/bisacrylamide (30%/ 0.8%, BioRad) gel and 
proteins then transferred to a nitrocellulose membrane (162-0115, BioRad). 
After blotting, the membrane was stained with Ponceau red. Subsequently, 
the membrane was blocked in 1 x PBS /0.05% Tween20 (Sigma)/ 5% milk 
(170-6404 BioRad) for an hour at RT. Incubations with primary and secondary 
antibodies described below were done in 1 x PBS/Tween 0.05%/ 1% blotting 
milk (BioRad) with 3 washing steps of 5 min shaking at RT and before 
developing the blot. Two polyclonal antibodies generated respectively against 
SmTOR peptide ed1 NH2-MSPSLVSYTQKNERGSHEVKIKHFSP-COOH (27) 
and against ShCRIT peptide ed2 NH2-SSTSDIRLVIHTKTGPIYIKST-COOH 
1:1000 were used in PBS/T 1:1000 (30), followed by goat anti-rabbit IgG HRP 
coupled (BioRad, #170-6515). The blot was developed using the ECLTM 
Western blotting detection system (Amersham Biosciences). Alternatively, a 
human monoclonal antibody against SmTOR peptide ed1 isolated from a 
human monoclonal antibody library (HuCAL) was used at a dilution of 1:1000 
(2.52 mg/ml stock) in PBS/T (AbyD04644.1, AbD Serotec, Martinsried). 
Mouse anti Histidine-tag:HRP (MCA1396P, Serotec) 1:3000 in PBS/T was 
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used as secondary antibody and the blot revealed as described above. The 
antibody was blocked by preincubation of AbyD0644.1 with a 100-fold molar 
excess of ed1 peptide in PBS/T for 60 min, RT and subsequent steps were 
performed as described above.   
 
Electron microscopy 
 
 Cercariae were fixed in 3% parafolmadehyde and 0.5% glutaraldehyde 
in 10 mM PBS (pH 7.4). After washing with PBS, they were treated with    
0.5% OsO4 for 30 min followed by dehydration in a series of graded ethanol 
solutions and embedding in LR White resin at 60 °C. Ultrathin sections 
(60 nm) were cut on an UltracutE Leica ultramicrotome and collected on 
copper 200 mesh grids. Grids were blocked in PBS / 2% BSA for 2 x 5 min. 
Polyclonal anti-ed1 or anti-ed2 antibodies described before were diluted in 
blocking buffer (1:50) and pre-immune serum was used as control. After 
incubation with primary antibodies for 2 h, grids were washed twice for 5 min 
with blocking buffer and incubated for 1 h with goat anti-rabbit IgG (EM-
GAHL10, British BioCell Laboratories) diluted 1:20 in blocking buffer. Final 
washings were performed followed by staining with 6% uranyl acetate, for 1 h, 
and then Millonigs lead acetate for 2 min. The sections were then dried, 
examined and photographed using a Philips Morgani transmission electron 
microscope.  
 
Cryosections and immunolocalisation 
 
 Thin sections (9 mM) of OCT embedded frozen S. mansoni cercariae 
were cut on a cryostat (Microm HM 560) and fixed in ice-cold methanol  
for 10 min. After blocking in 1 x PBS/ 3% BSA sections were stained with 
monoclonal antibodies against ed1 (AbyD04644.1 described above) 1:50 in   
1 x PBS/ 1% BSA or anti-GFP antibody (AbyD04652, AbD Serotec, 
Martinsried, 1.14 mg/ml stock) diluted to the according concentration for 2.5 h 
at RT. A fluorescein labeled goat anti-human IgG F(ab’)2 specific secondary 
antibody (# 109-095-006, Jackson Immuno Research Laboratories) was used 
at a dilution of 1:100 in PBS/BSA, 30 min, RT. Slides were mounted with 
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Vectashield fluorescence mounting medium (Vector Laboratories) and 
examined using LSM 510 META confocal laser scanning microscopy system 
(Carl Zeiss, Feldbach, Switzerland) with a Zeiss Plan Neofluar 63 x/1.25 
numeric aperture oil (∞/0.17) objective.	
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RESULTS 
 
S. mansoni TOR gene comprises four exons  
 
Thanks to S. mansoni genome sequence published on GeneDB website, 
we performed an alignment with S. japonicum mRNA sequence available in 
NCBI database in order to define exon/intron boundaries of the SmTOR gene. 
The analysis suggested the SmTOR gene comprised four exons, instead of 
the three suggested in GeneDB. Figure 1 represents the exon localisations 
along the Sm genome, showing that the gene contains three introns in the 
range of 2500 to 3500 bp, resulting in a 9721 bp length gene. The hatched 
boxes in Sj mRNA represent the 5’ and 3’ untranslated regions. The resulting 
transcript and protein would thus be longer than observed before (Inal, 1999). 
Thanks to this alignment, we were able to locate the ATG start codon of the 
SmTOR gene Smp_093840 at position 60992 in scaffold Smp_scaff000547. 
 
	
  	
  
Figure 1. Alignment of Sm (Schistosoma mansoni) genome (Smp_093840) 
and Sj (Schistosoma japonicum) mRNA of CRIT. Representation of the gene 
structure of SmCRIT exons and introns. The grey boxes represent the exons, 
the hatched boxes represent the sequences not found in Sm genome. 
Numbers indicate positions on scaffold Smp_scaff000547.  
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Cloning and sequencing of SmTOR exons  
 
We cloned the single exons from genomic DNA extracted from                      
S. mansoni cercariae using primers flanking the exons (Table 1). Separation 
of the PCR products by agarose gel electrophoresis showed bands at the 
expected size (Fig. 2A). The product for the amplification of exon 2 was 
expected to be 538 bp long but appears to be about 50 bp smaller. After gel 
extraction, cloning and sequencing of the single bands, the PCR product of 
exon 2 was found to be 481 bp long. The difference of 50 bp is because part 
of this region in the S. mansoni GeneDB is unknown and designated as 
multiple NNN. The length and sequencing results of the other 3 PCR products 
did match the information deposited at the S. mansoni GeneDB database. All 
the fragments were cloned at least three times and sequenced in both 
directions. Sequencing results of the single exons are in complete 
concordance with the cDNA sequence shown below in an alignment with 
SjTOR cDNA (Fig. 3). This delineation of sequencing information represents 
the merged information of single exon sequencing results. How the gained 
information is related to the GeneDB entry is listed in the next section.	
  	
  	
  	
  
	
  
Figure 2. Electrophoretic separation of PCR amplification products from 
S. mansoni genomic DNA or adult worm cDNA. (A) lanes 1 - 4 correspond to 
PCR amplification of exon 1 - 4 respectively, primers used Table 1. (B) 
SmTOR ORF amplified from adult worm cDNA, primers: SmTOR_ex1_-
15_fwd, SmTOR_exon4_rev (Table 1). 
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Expression of full-length SmTOR 
 
PCR amplification of SmTOR ORF from cDNA preparations from 
S. mansoni adult worms and cercariae generated with different primers (as 
described above) yielded the same result for all the reactions. Size- 
separation of reaction products amplified with smTOR_ex1_-15_fwd and 
smTOR_exon4_rev showed a single band at the expected size (Fig. 2B). The 
gel-purified and cloned fragments all held the 1260 bp sequence coding for 
full length SmTOR. The results were identical using different clones and 
performing sequencing reactions. The sequencing result for SmTOR cDNA is 
shown in alignment with SjTOR cDNA (AY814912) starting at the translation 
initiation codon (Fig. 3). When aligning the results from the single exons 
described in the previous section with the sequenced SmTOR cDNA the 
correlation was 100%. Splicing sites are marked with black arrows on the 
SmTOR cDNA (Fig. 3).  
Sequencing data for SmTOR cDNA perfectly match the corresponding 
sequences in the S. mansoni GeneDB database (positions 60991 to 70636, 
scaffold Smp_scaff000547) on S. mansoni genome (starting at ATG on exon 
1) for exons 1, 3 and 4 (single mutations differing between the clones and 
occuring at a frequency of 2 per 1260 bp were not taken into account). The 
gap in the S. mansoni GeneDB database lying within SmTOR exon 2  
(position 368 - 400 on SmTOR cDNA, 64816 to 64908, Smp_scaff000547 on              
S. mansoni GeneDB entry Smp_093840) could be filled in (Fig. 3). 
Furthermore we found 13 single nuclotide differences or gaps (indicated with 
stars in Fig. 3) within exon 2 in the range of position 348 to 400 when 
comparing S. mansoni GeneDB sequence and SmTOR cDNA. The newly 
sequenced SmTOR cDNA compared with the shorter SmTOR mRNA 
database entry (AF051138) of Inal (25) was nearly identical (18 single bases 
differed; the ATG is marked with a opened arrow (Fig. 3)). The former 5’ UTR 
region published at the same time for S. haematobium TOR (64 base pairs 
upstream of the former ATG) matches the sequence we now find to be part of 
exon 2 of the longer SmTOR version, with only 5 bases being altered (not 
shown). 
 
 29	
  
 
 30	
  
 
Figure 3. SmTOR and SjTOR cDNA alignment; identical nucleotides are 
linked with a bar. Filled triangles indicate the positions of splice sites on 
SmTOR cDNA (positions 214/215, 684/685 and 1009/1010, numbering with 
respect to the SmTOR start codon). Stars indicate mutations or gaps 
comparing sequencing data and GeneDB entry data; ATG of SmTOR 0.86 kb 
ORF (AF051138) is indicated by a triangle. Bases 368 – 400 were newly 
sequenced on S.mansoni cDNA and from genomic DNA as described.  
 
 
Developmental expression profiling of SmTOR as compared to SmTPI 
showed that the receptor mRNA was expressed at all the stages examined 
(Fig. 4). The receptor was expressed at higher level in cercariae as compared 
to schistosomula, adult worm, egg and miracidiae.  
The cDNA sequences aligned for S. mansoni and S. japonicum TOR 
show 46% homology at the nucleotide level.  
 
 
 
Figure 4. Quantitative RT-PCR analysis of SmTOR mRNA in different 
S. mansoni stages:  (1) eggs, (2) miracidiae, (3) cercariae, (4) schistosomu-
lae, (5) adult worm. Expression of SmTOR quantitated relatively to SmTPI as 
the control gene with bars representing 2-∆∆CT  values.   
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SmTOR translates into a protein similar in length to SjTOR and possesses 
four transmembrane domains  
 
SmTOR cDNA contains a 1260 bp open reading frame which should 
generate a protein of 419 amino acid length with a theoretical mass of 
46.7 kDa. Its amino acid sequence is shown in alignment with SjTOR, a 414 
amino acid protein based on proteomics data (41). Protein alignment of a 
possible SmTOR transcript and SjTOR shows 76.7 % homology on the 
protein level (Fig. 5).  
 
 
 	
  	
  
Figure 5. SjTOR and SmTOR protein sequence alignment. Identical amino 
acids are linked with a bar (76.7 % identity), similar amino acids are 
connected via “..” (84 % similarity). Exon/Intron boundaries on cDNA level for 
SmTOR are indicated with filled triangles. SmTOR protein (AF051138) 
starting with former extracellular domain 1 is marked by a triangle. 
Transmembrane domains 1-4 are shaded in grey as well as partially inserted 
helix 5. Domain designation: ed1, new extracellular domain 1; ed2, 
extracellular domain 2; id1, id2 intracellular domains 1 and 2.  
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Based on results from transmembrane prediction analysis we suggest 
SmTOR to have four transmembrane segments and a long C-terminal tail in 
homology with SjTOR (Fig. 6). In the absence of an N-terminal signal peptide, 
the transmembrane domain 1 (aa 31–53, Fig. 6) is most likely to function as a 
signal anchor sequence for ER targeting and membrane insertion, as 
predicted with the SignalP software. The four transmembrane segments have 
an alpha helical conformation predicted with high confidence, and the 
amphipathic alpha helix in the intracellular domain 2 is likely to be partially 
inserted into the plasma membrane. The domain organisation is the same for 
SmTOR and SjTOR. The overall transmembrane architecture remains the 
same as compared to the truncated protein version (UniProtKB/TrEMBL entry 
Q9U597) (42, 43).  
The 11 amino acids in the C-terminal part of ed1 that have been 
described to bind to C2 and interfer with its cleavage are boxed (Fig. 6). This 
sequence is different in SmTOR and SjTOR. 
 
 	
  
Figure 6. SmTOR protein model according to data generated with TopPred 
and PSIPREDView program. Numbers indicated refer to the first and last 
amino acid of the corresponding intra- or extracellular domain. The peptide 
sequence shown to bind C2 is boxed. Alphahelical transmembrane domains  
1–4 are at positions 32-52, 165-185, 199-219 and 236-256 respectively. 
Transmembrane domain one acting as signal anchor is shaded in grey.  
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Performing Western blot analysis of adult worm tegument preparations 
we detected a protein of about 55 kDa using antibodies generated against 
peptide sequences of ed1 and ed2 (Fig. 7). The same result was obtained 
using a monoclonal antibody generated against ed1 (Fig. 8A). Staining of 
cryosections of cercariae with the monoclonal antibody generated against ed1 
showed surface labeling, as compared to the negative control (Fig. 8B). The 
presence of SmTOR on the tegument surface was confirmed by electron 
microscopy. In sections stained with the polyclonal antibodies against SmTOR 
ed1 and ed2 respectively, immunogold labeling was detected at the tegument 
surface (Fig. 9).  
 
	
  
Figure 7. Western blot of adult worm tegument preparation. Polyclonal anti-
ed1, anti-ed2 antibody and pre-immune serum (lanes 1, 2 and 3 respectively).  
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Figure 8. SmTOR detection with a monoclonal anti-ed1 antibody 
AbyD04644.1 (A) Adult worm tegument preparation Western blot probed  
with monoclonal anti-ed1 (lane 1) or anti-ed1 preincubated with 100-fold 
excess of ed1 peptide as control (lane 2). (B) Immunofluorescent labeling of 
cryosections through cercariae. Anti-ed1 labeled section top left panel and 
anti-GFP labeld control section bottom left panel. 
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Figure 9. Localisation of SmTOR on tegument of cercariae using electron 
microscopy. Immunogold labelling is indicated by arrows. Sections stained 
with (A) polyclonal anti-ed1 antibody, (B) polyclonal anti-ed2 antibody and (C) 
pre-immune serum. Secondary antibody only was negative (not shown).  
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DISCUSSION 
 
The data presented here clarify the exon/intron gene structure of 
SmTOR and provide evidence that S. mansoni expresses the corresponding 
protein.  
We found that SmTOR gene structure contains four exons. A transcript 
containing the 1.26 kb SmTOR ORF showing 46% identity with the 1.25 kb 
SjTOR ORF was found in adult worm and cercariae cDNA preparations. The 
sequencing data generated not only complete the gaps present in the  
S. mansoni GeneDB for SmTOR, but also correct some likely sequencing 
errors present in the database entry (stars on SmTOR cDNA Fig. 3). The 
sequencing data are likely to be correct. SmTOR ORF presented here aligns 
with the previously described SmTOR ORF on mRNA entry AF0511378 from 
position 418 on (alignment not shown), and translates into a functional protein 
aligning with SjTOR. 
 SmTOR is expressed at various developmental stages of S. mansoni, as 
illustrated in Fig. 4. The highest expression was in cercariae, where we were 
able to detect it at the surface by confocal microscopy of cryosections  
(Fig. 8B) and electron microscopy (Fig. 9). The higher expression in cercariae 
as compared to adult worms has previously been described for the truncated 
receptor version (25). This observation is of interest since cercariae are the 
first to come into contact with the human skin, an encounter that might 
determine the fate of the infection. SmTOR might be essential at that specific 
time-point. Many complement proteins are produced by epidermal cells (44) 
and several authors have shown that complement proteins diffuse from the 
vascular compartment to the dermis and epidermis (45, 46). The complete 
complement cascade is active in the skin as indicated by the role of 
complement in many human blistering skin diseases (47). SmTOR might at 
that time help the parasite to escape complement attack.  
We had previously not been able to replicate the amplification of the 
short version ORF of the TOR receptor homologue from Schistosoma 
genomic DNA or from vertebrate genomic DNA of various sources (30). This 
is now understandable since the gene has three large introns not described 
previously. In addition, we did not find the sequence or fragments of it when 
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performing BLASTn searches on different vertebrate genomes. DeMarco et 
al. (48) recently analysed the controversy about the origin of schistosome 
albumin, and demonstrated it to be of hamster origin. In his discussion, he 
suggested that CRIT might be an example of reverse contamination from 
schistosome into the vertebrate samples. Our present data are in agreement 
with DeMarco’s comments. We must now consider our previous observations 
as being due to contamination and non-specific antibody stainings (30,  
49, 50).  
Previously, for both ShTOR and SmTOR, transcripts of 1.2 kb and 1.35 
kb cloned from adult worm cDNA libraries had been reported to contain an 
open reading frame of 0.86 kb, as proteins of 31.7 and 31.2 kDa were 
detected in adult worm preparations (25). Alignment of the region published 
as 5’ UTR of ShTOR (25) with SmTOR exon 2 sequenced  resulted in a 
nearly perfect match (alignment not shown). SjTOR cDNA and protein (41) 
are of the same length as we now found in S. mansoni. We therefore suggest 
SmTOR to be longer than originally described with the former ATG lying 
within the second exon of the gene. The translation initiation site we suggest 
for SmTOR does not lie in a classical Kozak sequence (51), but possible 
variation around the translation initiation codon has been reported for 
invertebrates (52).  
TOR protein had been shown on the surface of the adult worm by 
immunohistochemistry (25). We detected a band at approximately 55 kDa in 
adult worm tegument membrane preparation using two different polyclonal 
antibodies generated against ed1 and ed2 respectively (Fig. 7). The SmTOR 
amino acid sequence contains a potential N-linked glycosylation site at 
position 138. The protein detected might be the glycosylated form, as its 
theoretical molecular weight was calculated as 46.7 kDa. SmTOR in 
alignment with SjTOR protein shows 76% identity and 84% similarity (Fig. 5). 
TOR was found by Liu in S. japonicum in cercariae, schistosomula and adult 
worm (41), whereas no proteomic analysis of the schistosome tegument of 
adult worms identified peptides belonging to SmTOR (21, 53, 54). This might 
be due to the low abundance of the protein in the tegument of the adult worm 
(24).  
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Based on the secondary structure analysis described above we 
generated a hypothetical protein model for SmTOR (Fig. 6). SmTOR (or 
CRIT) was previously thought to span the membrane three times  
(hence the “T” for trispanning). The longer protein we found is very likely to be 
tetraspanning, as suggested also for SjTOR, which allows us to suggest a 
change in the name of the molecule, but without a change in the abbreviations 
used. The amphiphathic helix inserted partially in the membrane is present in 
SjTOR and SmTOR, although there is a high variability of amino acid 
sequence at this site between the two species.  
SmTOR had been renamed to CRIT (complement C2 receptor inhibitor 
trispanning) according to its putative function to bind C2. The former  
N-terminal extracellular domain ed1 of ShTOR as isolated peptide had been 
shown to bind C2 and with its C-terminal 11 amino acids designated as H17 
peptide being the active binding site (27). Incubation with this peptide has 
been shown to interfere with the binding of C2 to C4b and with C2 cleavage 
by complement C1s, thus blocking complement activation by the classical 
pathway. The new tetraspanning SmTOR protein still contains the same 
amino acid sequence in the extracellular domain 1 known to bind C2. Whether 
this sequence binds C2 in vivo on schistosomes remains to be explored, and 
it is interesting to note several differences in it between S. mansoni and 
S. japonicum (Fig. 5). It will be interesting to test if these differences alter C2 
binding to TOR/CRIT.   
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PART II: First extracellular domain of SmTOR: overexpression, 
purification, binding to C2 and antigenicity 
 
Results published in: Clinical & Experimental Immunology, (2012), 170(3), 
342-357  
 
ABSTRACT 
 
 Complement C2 had been identified as a ligand of a peptide sequence 
of the first extracellular domain of S. haematobium TOR (ShTORed1). To 
investigate, whether this binding would be maintained in the whole 
extracellular domain 1 of S. mansoni TOR (SmTORed1, 111 aa), we 
recombinantly overexpressed it as a N-terminally His-tagged fusion protein 
and used this 111 aa peptide purified by nickel affinity chromatography for 
subsequent testing. This purified rSmTORed1 bound C2 similarly to the 
peptide sequence of ShTORed1. We then used rSmTORed1 to see whether 
humans infected with S. mansoni develop specific antibodies to this domain. 
We found, that some patients with schistosomiasis (5/20), but also uninfected 
humans (4/40) do have antibodies against rSmTORed1. The specificity of 
antibody binding against SmTORed1 was evaluated by pre-incubation of 
serum dilutions with recombinant SmTORed1 produced as HaloTag fusion 
protein coupled to a solid support. The results of the competition ELISA 
showed, that IgG to rSmTORed1 detected were specific in 2/5 of the patients 
and 2/4 of uninfected individuals. These data indicate, that specific antibodies 
can be produced in patients, but evidently the antigen is not frequently 
recognised by the human immune system. That uninfected individuals have 
such antibodies might be related to the schistosoma that infest ducks and are 
responsible for swimmer's itch.     
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INTRODUCTION 
 
 The schistosoma TOR protein was originally identified in S. mansoni 
(SmTOR) and S. haematobium (ShTOR) (1) and later on suggested to be 
named complement C2 receptor inhibitor trispanning (CRIT), since the 27 
amino acid long ShTOR extracellular domain 1 (ed1) was shown to bind C2 
and interfere with its function in the complement cascade (2). This capacity 
was later on shown to depend the C-terminal 11 amino acids of ShTOR ed1 
domain or H17 peptide that even more effectively limited the extent of the C3 
convertase formation (3). As discussed above (Part I), Schistosoma TOR ed1 
is 111 aa long and the receptor described originally represents a truncated 
receptor version. The long extracellular domain 1 of the S. mansoni TOR 
receptor still contains the C-terminal H17 motif that binds C2 (2, 3). 
 Schistosome membrane proteins possessing signal peptides or signal 
anchors that direct their trafficking through the secretory pathway to the 
plasma membrane of the tegument, provide interesting vaccine targets as 
they are predicted to be in the contact with the host (4). Amongst the truly 
“exposed” vaccine candidates are the family of tetraspanins, four-pass 
transmembrane-domain proteins including a short (EC-1) and a longer (EC-2) 
extracellular loop. Beside Sm23 which is most efficacious when delivered as 
DNA vaccine (5), TSP-1 and TSP-2 extracellular loop 2 expressed as soluble 
fusion proteins in E. coli  turned out to be effective vaccine candidates (6). 
Screening of sera of either putatively resistant or chronically infected patient 
sera for specific antibodies against TSP-2 showed that the IgG antibody 
response was higher for putatively resistant individuals (IgG1 and IgG3 
subclasses), whereas chronically infected individuals failed to mount a 
detectable antibody response (6). Elevated levels of IgG1, IgG2 and IgG3 to 
recombinant antigen correlating with the human resistance status have been 
observed for other vaccine candidates, such as Sm14-FABP, Sm29 and 
SmStoLP-2 (7-9). These antigens produced and injected as recombinant 
proteins do confer protection against infection in mice (9-11). We assume, 
that SmTOR plays a major role in protecting the worms, and mainly the 
cercaria against complement attack, and due to its surface localisation, 
antibodies against SmTOR might in addition to its general effects block the 
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capacity of the worm to protect itself against complement.  
 In order to confirm its C2 binding capacity in vitro, recombinant 
SmTORed1 was overexpressed in E. coli and purified rSmTORed1 was 
obtained. This peptide was used to measure antibodies to rSmTORed1 in 
S. mansoni infected patients and uninfected humans. In addition, we used the 
purified His-tagged SmTORed1 to define its immunogenicity in mice and in a 
murine immunisation challenge model (Part III). We furthermore produced 
SmTORed1 as a Halo-tagged fusion peptide with a modified bacterial 
haloalkane dehalogenase tag (HaloTag) attached to the N-terminus (12) that 
could be covalently immobilised on beads. We used this construct in a 
competition ELISA to test the specificity of the anti-rSmTORed1 antibodies.  
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MATERIALS AND METHODS  
 
C2 binding ELISA 
 
 SmTORed1_27aa peptide and biotinylated (BT-) BT-SmTORed1_27aa 
were purchased from PT Peptides Technologies (Berlin, Germany).            
BT-SmH17, BT-SjH17, BT-C4beta, BT-SmH17scr and BT-SB78 were from 
Peptides and Elephants (Berlin, Germany). SmH17, SmH17scr and C4beta 
peptide sequences correspond to H17, H17S and C4β222-232 sequences 
described before (3). Sequence SB78 is an irrelevant scrambled peptide 
sequence. Sequence alignments were performed with ClustalW (13) and 
decorated using the BoxShade server facility. Purified human complement C2 
was purchased from CompTech (Tyler, TX, USA). 
 96-well plates (Maxisorp, Nunc) were coated overnight at 4 °C with 
peptide (500 nmoles/well) or NeutrAvidin (Pierce; 0.5 mg/well) in 0.1 M 
bicarbonate buffer, pH 9.6. Plates were the either blocked for 1 h, RT with      
5 % BSA in 1 x PBS/0.05 % Tween 20 (PBST) or incubated with 500 nmoles 
biotinylated peptide in 1 x PBS, RT (in the dark) and then blocked with 5 % 
BSA/PBST. For the C2 binding assay with all the different biotinylated (BT) 
peptides (Fig. 1), BT-peptides were first bound to the plate (1 x PBS, 500 
nmoles/well) and then free binding sites blocked free biotin for 1 h, RT          
(1 x PBS, 900 ng/well). After blocking, C2 was diluted in binding buffer 
(amounts as indicated in figures) and incubated 1 h at RT. Plates were 
washed 5 times with PBST (as it was done for all the washing steps), 
incubated with anti-C2 antibody (Calbiochem) diluted 1:5'000 in PBST  
for 45 min, RT. After additional washes, plates were incubated with                  
donkey anti-goat HRP, 1: 10'000 in 1 x PBS, 30 min, RT. Plates were washed 
and developed by incubation with a TMB peroxidase substrate (BD 
Pharmigen). The absorbance was measured at 450 nm.          
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Expression of recombinant extracellular domain 1, purification and 
solubilisation 
 
 SmTORed1 ORF was cloned into the pET15b expression vector 
(Novagen) by sticky-end PCR method (14) using the NdeI and BamHI 
restriction sites and pCR2.1-TOPO SmTOR (15) as template. The primer 
pairs used were for PCR 1: 5'-TATGCCGAGACTTATTCCAGAGGATAAT-3' 
(forward1) and 5'-GATCCTTAGTAAGGACTGAAATGCTTTAT-3' (reverse1), 
for PCR 2: 5'-TGCCGAGACTTATTCCAGAGGATAAT-3' (forward2) and       
5'-CGATCCTAGTAAGGACTGAAATGCTTTAT-3' (reverse2). Sticky-end PCR 
was performed as described in brief: two different PCR reactions were 
performed, reaction products were cleaned up separately by agarose gel 
electrophoresis and purification of the bands at the expected molecular weight 
(345 bp) using the QIAquick gel extraction kit (QIAGEN). The extracted DNA 
was then mixed in equimolar ratio (1:1), denatured at 95 °C, 5 min and then 
let re-anneal on ice and used for ligation into digested and cleaned-up vector. 
pET15b vector was prepared by double digestion with NdeI and BamHI (NEB) 
and purified as described above. Ligation was performed using Quick Ligase 
(NEB) and the mixture was transformed into TOP 10 bacteria (Invitrogen) and 
grown on LB agar plates containing 100 µg/ml ampicillin (Sigma). Clones 
were analysed by restriction enzyme digestion with SalI (NEB) cutting at 
position 244 of the insert sequence. Positive clones were sequenced and 
used for transformation into a bacterial expression strain.  
 SmTORed1pET15b was transformed into BL21 (DE3) bacteria for 
protein overexpression. Batch cultures were grown in auto-induction media as 
described by Studier (16). Pre-cultures were grown in MDAG non-inducing 
medium and main cultures were grown in MDA-5052 auto-inducing medium, 
both supplemented with 100 µg/ml carbenicillin (Sigma). Single clones of 
SmTORed1pET15b (rSmTORed1 purification) or pET15b (mock transfection, 
purification of control fraction) transformants were picked and pre-cultures 
were grown overnight at RT with shaking at 220 rpm and subsequently diluted 
1:50 in MDA-5052 medium for protein expression. 50 ml main cultures in    
250 ml Erlenmeyer flasks were shaking at 250 rpm for 18 h, RT. Bacteria 
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were harvested by centrifugation and pellets frozen at -20 °C till required. 
      Recombinant protein was purified from the insoluble cytoplasmic 
fraction (inclusion bodies) of SmTORed1pET15b transformed BL21 (DE3) 
bacteria. Bacteria were lysed using BugBuster bacterial cell lysis detergent 
(Novagen) supplemented with EDTA-free protease inhibitor cocktail (Roche 
Diagnostics) and inclusion bodies were purified by repeated centrifugation 
and washing steps as described in the pET system manual (Novagen). The 
final inclusion body pellet was resuspended in 10 ml denaturing buffer 
containing 10 mM imidazole (50 mM NaH2PO4, 500 mM NaCl, 6 M Guanidine 
hydrochloride, pH 8 + 10 mM imidazole). The recombinant protein was then 
purified by metal affinity chromatography using ÄKTAprime plus system (GE 
Healthcare Biosciences). A 5 ml Ni-NTA Superflow Cartridge was equilibrated 
with denaturing buffer/10 mM imidazole (buffer A) and 5 ml of solubilised 
sample loaded onto the column (1 batch cleaned up corresponded to 25 ml 
original bacterial culture). The column was then washed with 5 bed volumes 
of denaturing buffer and then eluted with 10 - 250 mM gradient of imidazole in 
denaturing buffer in V = 100 ml. Fractions containing the main protein peak 
were pooled and analysed by SDS-PAGE (15 %). Purified His-tagged 
rSmTORed1 was refolded by step-wise dialysis. First, the sample (in a 
volume of 20 - 25 ml denaturing buffer/imidazole) was dialysed into refolding 
buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA, 400 mM L-arginine) at 4 °C 
overnight using a dialysis membrane of 3500 molecular weight cutoff 
(Spectrum Laboratories). Two additional dialysis steps against 1 x PBS were 
then performed for 3 h at 4 °C each. The purity of the sample and 
concentration were then evaluated analysing an aliquot by 15 % SDS-PAGE 
and bands visualised by Coomassie staining (Instant Blue, Expedeon). 
Molecular weight markers used were Precision Plus Protein standards 
(BioRad) and BenchMark ladder (Invitrogen). Protein concentration in the 
sample was determined using DC protein assay (BioRad). The Coomassie 
stained protein band at the expected molecular weight was excised and 
analysed by in-gel tryptic digestion and LC-MS/MS analysis (17).    
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Characterisation of SmTORed1 by Western Blot and ELISA 
 
 Western blot using anti-ed1 antibody AbyD04644.1 (Serotec) was 
performed as described above (Part I). Protein samples were run on a 
standard 15 % acrylamide/bisacrylamide gel (BioRad) and transferred to a 
nitrocellulose membrane. The membrane was blocked in PBST/5 % milk 
followed by incubations with primary (AbyD04644.1, 1:1000) and secondary 
antibody (goat F(ab')2 anti-human IgG-HRP, Serotec, 1:3000) in PBST 1 % 
milk, 1 h RT each. The blot was developed with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce).  
 The protocol for C2 binding ELISA was the same as described in the 
previous paragraph. AbDy04644.1 (2.51 mg/ml stock) diluted in PBST was 
used at dilutions ranging from 1:1000 to 1:10'000 to detect rSmTORed1 by 
ELISA. The amounts of anti-GFP AbDy04652.1 corresponding to the highest 
and lowest dilution respectively (1.14 mg/ml stock) were used as negative 
controls. Peptide was immobilised as above, blocked in 5 % BSA/PBST, 1 h, 
RT followed by 30 min incubation with primary antibody. Secondary antibody 
(goat F(ab')2 anti-human IgG-HRP, Serotec) was diluted 1:10'000. Incubation 
time was 30 min, RT and the ELISA was then developed as done before.   
  
Anti-rSmTORed1 antibody measurement in human sera 
  
 Patient sera were archived anonymised sera from S. mansoni infected 
patients (provided by the SwissTPH Institute, Basel). Sera had been tested 
positively for antibodies against soluble worm antigen (SWA) and soluble egg 
antigen (SEA) and by immuno fluorescence antibody tests (IFAT) as done at 
the SwissTPH Institute. Normal human serum samples were collected at the 
Blutspendezentrum, Basel.  
 Nunc Maxisorp 96-well plates were coated with 1 µmole rSmTORed1 
per well diluted 0.1 M bicarbonate buffer, pH 9.6 overnight at 4 °C. Plates 
were washed 3 times with PBST and serum samples diluted 1:500 in PBST 
were added for 45 min, 37 °C. After incubation with sera, plates were washed 
5 times with PBST and biotinylated secondary antibody diluted 1:10'000  
was added to each well (goat F(ab')2 anti human IgG, Biosource) for 1 h, RT. 
 50	
  
This was followed by additional 5 washes and 30 min incubation with    
Streptavidin-HRP (Pierce, 1:10'000 in 1 x PBS) at RT. After washing as in the 
previous steps, ELISA was developed using TMB peroxidase substrate and 
the absorbance at 450 nm was measured. 
         
Cloning of HaloTag fusion constructs 
 
 All N-terminal HaloTag fusion constructs were cloned with the primers 
listed in Table 1 into the bacterial T7 promotor based expression vector 
pFN18A HaloTag T7 Flexi Vector (Promega, Madison, WI, USA). The 
barnase positive selection cassette was removed by digestion of pFN18A with 
PvuI and PmeI and replaced by HALOfwd and HALOrev annealed oligos as 
described before (18). The construct pFN18A Halo expressing HaloTag only 
was used as negative control. Halo-SmTORed1 (111 aa) and Halo-C4beta 
(C4beta: 26 aa corresponding to C4β206-232 peptide stretch) were amplified 
from pCR2.1-TOPO SmTOR (15) for the SmTORed1 constructs or Hep2G 
(human hepatoma cell line) cDNA for the C4beta chain peptide. Cloning was 
performed with the sticky-end PCR method (14) using iProof High-Fidelity 
DNA Polymerase (Bio-Rad) and the so generated inserts were ligated into 
PvuI/PmeI digested pFN18A vector with Quick Ligase (New England Biolabs). 
Plasmids were propagated in TOP10 E.coli (Invitrogen) and open reading 
frames verified by sequencing.   
 
Table 1. Primer list used for cloning of Halo-tagged fusion constructs.  
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Over-expression and purification of Halo-tagged peptides  
 
 Plasmids (pFN18A HALO, pFN18A HALOed1 or pFN18A HALO C4 
beta) were transformed into chemically competent BL21 (Sigma). Single 
clones were picked from LB/Amp plates and were grown overnight at 37 °C 
(at 220 rpm) in 2 ml LB medium supplemented with 100 µg/ml Ampicillin 
(Sigma). Pre-cultures were diluted tenfold in LB/Ampicillin and when grown to 
an OD600 of > 0.6 induced with 1 mM IPTG. Aliquots of the cultures were 
screened for expression of target gene 3 - 5 h after induction by SDS-PAGE 
and Coomassie staining. Total cell protein fractions were prepared using 
PopCulture reagent (Novagen) according to the protocol in the pET system 
manual (Novagen). Theoretical molecular weights of the fusion constructs 
were calculated as 35.4 kDa (HALO), 38.5 kDa (HALO C4 beta) and 48.2 kDa 
(HALO ed1).  
 In order to purify Halo-tagged constructs, bacteria cultures (V = 20 ml) 
were pelleted, resuspended in BugBuster mix (Novagen) and soluble 
cytoplasmic fractions were prepared according to the manufacturer protocol. 
Protein samples were then prepared for coupling onto magnetic beads 
(HaloLink, G9311, Promega). Buffer exchange into 1 x PBS was 
accomplished by using 3'000 MWCO Amicon Ultra Centrifugal Filter Devices 
(Milipore). Halo-protein concentrations were estimated in comparison with 
marker protein bands (BenchMark Protein Ladder Invitrogen; each protein 
present at a concentration of approximately 0.1 µg/µl). For the coupling 
reaction, samples were diluted at the appropriate concentrations in 100 mM 
TrisHCl, pH 7.5, 150 mM NaCl, 0.01 % NP40. HaloTag fusion proteins were 
immobilised on magnetic beads as described in the instruction manual 
(G9311, Promega). Magnetic beads were incubated with the HaloTag fusion 
proteins in excess in order to ensure that equal amounts of protein i.e. beads 
were used in the assay. This was the case because the covalent bond 
formation between HaloTag and chloralkane linker is specific and highly 
irreversible (12). After coupling reactions, beads were washed extensively in 
PBS and used for competition ELISA or peptide purification. An amount of 
40 µg Halo-tagged protein was coupled onto 20 µl beads in gel slurry that was 
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then used in the competition ELISA. 
 
Competition ELISA assay 
 
 For competition ELISA, 96 well plates were coated as described above 
but with 500 nmoles rSmTORed1 per well. Anti-rSmTORed1 antibody 
measurement in human sera was performed exactly as described above, but 
sera were first incubated with Halo-tagged fusion constructs as described as 
follows. 20 µl washed beads with immobilised HALO or HALOed1 were 
resuspended in 250 µl PBST. 1 µl of serum sample (resulting in a serum 
dilution of 1:250) was added and the mix incubated on a wheel for 20 min, RT. 
As a control, 1 µl of serum sample was diluted in 250 µl PBST and incubated 
in parallel without beads. The coated ELISA plate was washed and 50 µl of 
PBST added per well. Magnetic beads were removed after incubation time 
and 50 µl of depleted serum (or control sample) was added per well 
(experiments were done in triplicates), resulting in a final serum dilution of 
1:500. Plates were incubated at 37 °C, 45 min and proceeded with the 
protocol as described above.   
 
Mouse Ig detection to rSmTORed1 or peptides purified from HaloTag fusion 
proteins  
 
 40 µg Halo-tagged protein on beads was incubated with ProTEV 
protease (Promega, #V6051) in a total reaction volume of V = 200 µl in order 
to get cleaved peptide in solution at a concentration of 0.2 µg/µl. Cleavage 
was performed according to instruction manual provided. Cleavage of 
HaloTag fusion peptides occurs in the 16 aa linker sequence (N-terminally to 
the peptide sequence) EPTTEDLYFQ/SDNAIA between Q and S (TEV 
protease cleavage site EXXYXQ(G/S)) releasing the peptide of interest with 
the C-terminal 6 aa (SDNAIA) attached. After completion of cleavage, 
magnetic beads were removed. 96-well plates (Maxisorp, Nunc) were coated 
overnight at 4 °C with cleaved peptides or rSmTORed1 (500 nmoles/well) in 
0.1 M carbonate bicarbonate buffer, pH 9.6. Plates were blocked in      
PBST/5 % BSA for 1 h, 37 °C. and washed 5 x with PBST (as all the  
 53	
  
following washes). Mouse serum samples from BALB/c mice immunised  
with rSmTORed1 in Complete/Incomplete Freund’s (all described in  
Part III) adjuvant were diluted 1:25'600 in 100 µl PBST and plates  
were incubated for 1 h, RT. After washes biotinylated primary antibody                                   
(Goat anti-mouse IgG+IgM+IgA, ab6005, AbCam) diluted 1:10'000 in PBST 
was added for another hour at RT. Bound antibody was detected with 
streptavidin-HRP (Pierce) diluted 1:10'000 in PBS (30 min, RT) and the  
ELISA was developed by incubation with a TMB peroxidase substrate. The 
absorbance was measured at 450 nm.          
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RESULTS 
 
The C-terminal 27 amino acids of SmTORed1 and ed1-derived peptides bind 
purified C2 
 
 We compared the binding of C2 to different synthetic peptides derived 
from the SmTORed1 sequence measured by ELISA. The C-terminal 27 amino 
acids of S. haematobium TOR extracellular domain 1 show 92.6 % sequence 
identity with the corresponding sequence found in S. mansoni TORed1     
(Fig. 1A). C2 binds in a concentration dependent manner to SmTORed_27aa 
peptide immobilised directly on the ELISA plate (Fig. 1B) and to the 
biotinylated peptide BT-SmTORed1_27aa captured on a NeutrAvidin-coated 
plate (Fig. 1C). In both cases, the binding buffer was 1 x PBS containing    
150 mM NaCl. Binding of C2 to the uncoated plate was in the range of 
background OD levels. A panel of biotinylated ed1-derived peptides (Fig. 1D) 
was immobilised the same way to test for C2 binding. C2 in 1 x PBS buffer 
with salt adjusted to a final concentration of 180 mM NaCl, generating a 
medium salt binding buffer, did specifically bind to SmTORed1_27aa, but not 
specifically to the other peptides tested (Fig. 1E). This difference in C2 binding 
was not observed when 1 x PBS or under high salt conditions in 1 x PBS 
containing 250 mM NaCl were used as buffers instead (not shown). In             
1 x PBS, C2 did bind unspecifically to all the peptides, in high salt buffer no 
binding to any of the peptides was detectable. As negative control, C2 was let 
to bind in the corresponding buffer on the plate and the primary antibody was 
omitted in detection process, which resulted in OD values as low as the blank 
OD values for all of the biotinylated peptides (OD450 = 0.04 - 0.07; not shown).   
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Figure 1. C2 binding on SmTORed1-derived peptides. (A) Amino acid 
sequence alignment of C-terminal 27 amino acids S. mansoni and 
S. haematobium TORed1 domains termed SmTORed1_27aa and 
SmTORed1_27aa respectively. Sequence alignments were performed with 
ClustalW2. The regions with high identity and similarity between peptide 
sequences are shaded in black and grey. (B, C) C2 binding (in 1 x  
PBS) ELISA to immobilised SmTORed1_27aa (B) or biotinylated (BT-) 
SmTORed1_27aa peptide (C). ELISA Results are expressed as means of 
individual measurements. Error bars indicate S.D. of the means. (D) 
Alignment of SmTORed1_27aa sequence with SmH17, SjH17 (C-terminal 11 
aa of S. mansoni and S. japonicum ed1), C4beta (human C4β chain peptide 
F222), scrambled peptide SmH17scr and a control peptide SB78. (E) C2 
binding on different biotinylated peptides with sequences listed in (D). 1 x 
PBS/180 mM NaCl was used as binding buffer. 
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Recombinant SmTORed1 overexpression in E. coli, purification and 
characterisation 
 
 SmTORed1 ORF was cloned into a pET15b vector and subsequently 
transformed into bacteria in order to produce the N-terminally His-tagged 
fusion protein rSmTORed1 containing only a short linker sequence (Fig. 2A). 
BL21 (DE3) bacteria transformed with pET15bSmTORed1 were grown in 
auto-induction media and rSmTORed1 was purified from inclusion bodies  
by Ni2+-affinity chromatography. Fractions eluted from the FPLC column  
were pooled (as described in the method section) and the denaturing  
buffer was exchanged by step-wise dialysis against 1 x PBS. An aliquot of the 
preparation was analysed by gel electrophoresis before and after the final 
centrifugation step and a protein band of the calculated molecular weight of 
14.7 kDa was detected (Fig. 2B). The protein band was sequenced by mass 
spectrometry and fragments belonging to recombinant SmTORed1 were 
detected (Fig. 2A). The preparation did not contain any impurities that could 
be visualised by Coomasie blue staining and only a small portion of 
rSmTORed1 was not soluble in 1 x PBS. The protein concentration of total 
compared to soluble peptide was 145 ng/µl and 132 ng/µl respectively for the 
peptide batch shown. Pooled protein fractions analysed before re-folding into 
1 x PBS showed an additional protein band at an approximate molecular 
weight of 30 kDa (Fig. 2C). Recombinant SmTOed1 as well as the 30 kDa 
protein band, that presumably is the peptide dimer, were detected by Western 
blot using monoclonal anti-ed1 antibody (Fig. 2C). The same monoclonal 
antibody did recognise plate-bound rSmTORed1 (Fig. 2D), which was also 
shown to bind C2 (Fig. 2E).   
 
 
 
 
 
 
 
 
 57	
  
 
Figure 2. Production of His-tagged SmTORed1 in E. coli and molecular 
characterisation of purified peptide by mass spectrometry, Western blotting 
and ELISA. (A) SmTORed1 peptide sequence with the 6 x His-tag and linker 
sequence (10 aa) originating from the pET15b vector shaded in grey. 
Fragments identified by mass spectrometry are underlined. (B) SDS-PAGE 
analysis of purified rSmTORed1 after Ni2+ chromatography (pooled  
eluates) and refolding into 1 x PBS. Total amount of peptide in buffer was 
analysed before (total, lane 2) and after removal of residual precipitate by  
centrifugation (soluble, lane 3). 4 µl of sample was loaded per lane. Lane 1 
(marker): BenchMark Protein Ladder. Protein bands are visualised by 
Coomassie stain. (C) Pooled fractions of FPLC-purified peptide analysed 
before dialysis into 1 x PBS. 20 µl sample was loaded per lane. Peptides 
detected by Coomassie Blue (left) and by Western blot using monoclonal anti-
ed1 antibody AbDy04644.1 (right). (D) Peptide ELISA showing AbDy04644.1 
specifically binding purified rSmTORed1, as compared to the isotype control 
antibody (AbDy04652.1). (E) C2 binding on a rSmTORed1 coated ELISA 
plate, binding in 20 mM Tris buffer + 1 mM MgCl2 + 1 mM CaCl2. ELISA 
Results are expressed as means of individual measurements. Error bars 
indicate S.D. of the means.  
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Human anti-rSmTORed1 antibodies detected in S. mansoni infected and 
uninfected individuals 
 
 We evaluated by ELISA the reactivity of anti-rSmTORed1 antibodies in 
sera of individuals that were infected with S. mansoni, as classified by positive 
titers against soluble worm and egg antigen (SWA/SEA) and immuno- 
fluorescence antibody tests (IFAT), and in uninfected individuals. IgG 
antibodies to rSmTORed1 were detected in 5 out of 20 patients (25 %) 
infected with S. mansoni, but also in 4 out of 40 uninfected individuals (10 %) 
living in Switzerland (Fig. 3). The positive signal threshold was set arbitrary 
considering the relative fold increase values indicated.  
 
Figure 3. Measurement of antibodies to rSmTORed1 by ELISA. Total IgG 
levels in patients (archived anonymised sera, purple box) and NHS (green  
box) normalised to control serum (MO, grey bar). The black solid line set  
at 1 corresponds to the mean of absorbance measuring control serum MO 
(mean OD ± S.D (n = 9): OD450 nm = 0.176 ± 0.05), that was set to 1 in order to 
picture patient and NHS values normalised to one control serum value. The 
dashed black line was set at an arbitrary treshold and marks the lower limit of 
a fold-increase value considered as postive signal. 5 (filled purple bars) out of 
20 patients and 4 (filled green bars) out of 40 patients were tested as positive. 
The results of three different experiments done in duplicates are shown. Error 
bars indicate S.D. of the means.  
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Production of HALO-tagged ed1 and C4β chain stretch as bacterial fusion 
proteins used for competition ELISA covalently coupled to magnetic beads  
 
 Halo-tagged peptides can be covalently immobilised on a solid support 
and be used in competition ELISA assays. SmTORed1 peptide and the 
homologous sequence on the C4β chain peptide aligning with it were 
produced as N-terminal Halo-tagged fusion proteins, schematically pictured in 
Fig. 4A, and were used linked to magnetic beads in a competition ELISA 
together with HaloTag on magnetic beads alone or as an alternative method 
to purify recombinant peptides (described in the method sections and the 
following results sections). E. coli strains transformed with pFN18AHALO, 
pFN18AHALOC4beta and pFN18AHALOed1 were grown to an OD600 > 0.5  
in LB medium and were overexpressing the corresponding fusion protein 
upon induction with 1 mM IPTG (Fig. 4B).  Aliquots of the crude soluble E. coli 
fractions were separated by SDS-PAGE 3 h after induction of protein 
overexpression and protein bands were visualised by Coomassie blue  
staining. Protein bands of 35.4 kDa, 38.5 kDa and 48.2 kDa corresponding  
to the theoretical molecular weights calculated for HaloTag (lane 2), 
HaloC4beta (lane 3) and HALOed1 (lane 4) were detected. HALOed1 but  
not HALOC4beta or HaloTag alone was also detected by Western blot  
probed with monoclonal anti-ed1 antibody AbDy04644.1 (Fig. 4C). Thus, this 
monoclonal antibody does not show any cross-reactivity with the C4β chain 
peptide homologous to the 27 C-terminal amino acids of SmTORed1.   
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Figure 4. SDS-PAGE (10 %) analysis and immunoblotting cell extracts  
from E. coli transformed with pFN18AHALO, pFN18AHALOC4beta and 
pFN18AHALOed1. (A) Schematic representation of HaloTag fusion peptides 
generated. The HaloTag protein (boxed) is attached N-terminally to the 
sequences of interest via a 16 aa linker containing a TEV protease cleavage 
site. The 6 C-terminal amino acids of the linker sequence remaining attached 
to the peptides after cleavage are shown (underlined). HaloTag protein linked 
to SmTORed1 loop is denoted as HALOed1 and HaloTag fused to a 26 aa 
C4β chain stretch is termed HALOC4beta (human C4β chain peptide S206). 
Local sequence alignment over the C-terminal 27 aa was performed with 
ClustalW2 and then manually edited (identical amino acids in bold letters, 
similar amino acids shaded in grey). (B) Coomassie stained gel with protein 
extracts from recombinant E. coli (BL21) overexpressing HaloTag (lane 2), 
HALOC4beta (lane 3) or HALOed1 (lane 4) analysed 3 h after induction with    
1 mM IPTG and resolved by SDS-PAGE. Lane1: Molecular weight marker. 
(C) Protein samples extracted from BL21 4.5 h after induction with IPTG. 
HaloTag (HALO) and Halo-tagged (HALOC4beta, HALOed1) peptides in 
crude E. coli extracts visualised by Coomassie stain (left) and detected by 
Western blot probed with monoclonal anti-ed1 antibody AbDy04644.1 (right). 
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Some patients and uninfected humans have specific antibodies against 
rSmTORed1 
 
 The 5 schistosomiasis patients and 4 uninfected individuals considered 
to have antibodies against rSmTORed1 measured by ELISA (Fig. 3) were 
tested in a competition type ELISA. The specificity of antibody binding against 
SmTORed1 was evaluated by preincubation of diluted patient sera with   
Halo-tagged ed1 or HaloTag alone coupled to magnetic beads. Competition 
ELISA results show, that 2 out of 5 schistosomiasis patients (Fig. 5A) and  
2 out of 4 uninfected individuals (Fig. 5B) have specific anti-rSmTORed1 IgG 
antibodies whose binding on the peptide could be abolished by preincubation 
of diluted sera with HALOed1, but not with HaloTag alone. This decrease in 
signal (indicated by an arrow) was significant for the patient sera 4466 and 
2006-0059 (Fig. 5A) and uninfected human 42 and 4 sera (Fig. 5B) except 
one (serum 25740) that had shown the highest positive values measured 
before (Fig. 3). In the sera tested with positive signals just above the arbitrarily 
set threshold value, namely the patient sera 4745, 3548, 4938 (Fig. 5A) and 
uninfected human serum 25630 (Fig. 5B) there were no specific antibodies 
detected. In retrospective, NHS 4 and NHS 42 were confirmed to have no 
detectable levels of anti-SWA and anti-SEA antibodies.  
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Figure 5. Measurement of antibodies to rSmTORed1 by ELISA and 
confirmation of specificity by competition ELISA using Halo-tagged bead-
bound fusion constructs. OD450 values measured were normalised to mean 
values recorded for the control sample (MO, OD450 nm = 0.243 ± 0.06, n = 7) 
and indicated as fold increased values. Prior to IgG measurement, individual 
sera were preincubated with Halo constructs coupled to magnetic beads: no 
competition (sample + no beads), with HaloTag alone (sample + HALO) or 
Halo-SmTORed1 (HALOed1). Measurement of IgG specificity in 
schistosomiasis patients (A) and uninfected human sera (B). Stars indicate 
specific IgG to rSmTORed1 in the corresponding serum, tested by 
competition ELISA. Bars represent the mean values of three independent 
experiments. Error bars indicate S.D. of the means. Arrows indicate a 
significant decrease (> 40 %) in signal due to depletion of specific antibodies 
by pre-incubation with HALOed1. 
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Antibodies against rSmTORed1 generated in mice do not recognise the 
homologous stretch on the complement C4 β chain 
 
 Since there are described homologies between SmTORed1 and the 
C4beta chain, we tested for possible cross-reactions. BALB/c mice vaccinated 
with purified rSmTORed1 (see Part III) do generate antibodies against 
rSmTORed1 that do not cross-react with the 27aa region in the C4β chain 
aligning with the ed1 domain (Fig. 6, Fig. 4A). Antibodies to rSmTORed1 can 
be detected equally well when Ni2+ purified His-tagged peptide or ed1 
generated as Halo-fusion protein subsequently cleaved off in the peptide 
purification procedure are immobilised. Neither immunised nor control 
immunised mice recognise the inclusion body control fraction that is the Ni2+ 
purified insoluble fraction of bacteria transformed with empty pET15b vector. 
 
 
Figure 6. Total Ig detection in sera of individual BALB/c mice immunised with 
rSmTORed1 (n =3; mice 1.1 - 1.3) and a control mouse injected with PBS 
only (mouse 3.1). Pre-immune sera (bleed day -7) and sera obtained after the 
first boost (day 35) were diluted 1:25'600. Ig response measured to 
rSmTORed1, to TEV cut rSmTORed1, rC4beta 27aa and HALO control 
(purified as Halo-tagged peptides or Halo-tag alone subsequently cut with 
TEV protease- peptide sequences shown in Fig. 4A) and to E. coli inclusion 
bodies. Results are expressed as means of individual measurements. Error 
bars indicate S.D. of the means.  
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DISCUSSION 
 
 
 Complement C2 had been first identified as a ligand of S. haematobium 
TOR by receptor affinity chromatography (2). ShTORed1_27aa was 
subsequently shown to bind C2 by chemical cross-linking assay, using the 
homologous C4β chain sequence as binding control, and to interfere with C2 
cleavage by C1s and thus prevent its interaction with C4b resulting in 
inhibition of CP C3 convertase activity. Consequently there is a reduced 
hemolysis of sheep erythrocytes (SRBC) in the presence of peptide (3).  
 We were investigating the C2 binding to the C-terminal 27 amino acids 
of SmTORed1 (SmTORed1_27aa). The sequences of ShTORed1_27aa, that 
has been studied before, and SmTORed1_27aa are not identical (Fig. 1A). 
We show, that SmTORed1_27aa binds C2 in a concentration dependent 
manner in an ELISA setup when the peptide was conventionally immobilised 
in carbonate buffer (Fig. 1B), or to biotinylated SmTOR_27aa captured on a 
NeutrAvidin coated plate (Fig. 1C). This suggests, that C2 might bind to the  
C-terminal 27 amino acids of S. mansoni and S. haematobium TOR ed1 
domain.  
 In previous work it was shown that the complement inhibitory 
characteristics of ShTORed1_27aa were also found, and even to a higher 
degree, in the shorter H17 peptide (11 amino acids). This sequences was 
very similar to a sequence found in C4β222-232  which inhibited complement as 
well. Here we could not demonstrate in an ELISA assay any specific binding 
of C2 to this C4β222-232 chain and the Sm/ShTOR H17 peptide (Fig. 3E).  
 These later results contrast with the binding of the long peptide (27 aa) 
of both SmTOR and ShTOR, which despite two amino acid difference had the 
same sequence for the 11 aa corresponding to H17. Thus it is likely, that the 
11 aa are involved in C2 binding but for us not demonstrable because of non-
significant binding or buffers or other interactions due to biotin for  
example. Of interest the binding of the biotinylated 27 aa peptides were  
strongly dependent on buffers. We had to increase the salt concentration to  
180 mM NaCl, as compared to the one found in 1 x PBS routinely used in  
the lab (150 mM). In 1 x PBS we did only observe unspecific C2 binding to  
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the peptides, and using a 1 x PBS buffer containing 250 mM NaCl did 
abrogate all the C2 binding. This suggests, that specific C2 binding to the  
27 aa peptide in an ELISA system only occurs under certain conditions  
with salt adjusted in 1 x PBS when peptide is presented in solution (bound to 
NeutrAvidin) and only to the full-length 27 aa sequence. In agreement with 
previous work (19), this binding was not magnesium dependent.  
 These data emphasise, that the interactions between C2 and SmTOR 
are very dependent on the physicochemical environment. However, that the 
27 aa sequence might bind better than the 11 aa sequence (H17) could be 
related to more homologies between a larger stretch of C4β212-231 chain with 
the 27 aa sequence of SmTOR than the homologies between the shorter 
C4β222-232 chain sequence and H17.  
 Because we planned to test the immunogenicity of the SmTORed1 
domain, we set up a system to overexpress and purify it. Recombinant His-
tagged SmTORed1 was produced in defined rich media by auto-induction 
(16), because the overexpression of rSmTORed1, with its ORF under the 
control of the lac repressor on the pET15b plasmid (20) was not manageable 
when bacteria were grown in LB medium and protein expression was induced  
with IPTG. This was possibly due to the basal expression of rSmTORed1  
that was toxic for the bacteria. By using auto-induction media for bacterial 
overexpression, we could circumvent this problem and in addition produce 
high amounts of proteins in cultures reaching high densities without 
detrimental effects on bacterial viability.   
 His-tagged SmTORed1 needed to be purified to yield a not too highly 
concentrated protein solution in order to avoid protein precipitation in the 
course of denaturant removal, that was most likely due to the formation  
of peptide dimers visible in highly concentrated eluates (Fig. 2C). This 
phenomenon was also observed to occur in the case of the vaccine candidate 
Sm14, where protein dimerisation and subsequent aggregation led to a 
reduction in vaccine efficacy (21). Optimised rSmTORed1 purification under 
denaturing conditions and refolding in to 1 x PBS under optimised conditions 
yielded reasonable amounts of soluble protein of up to 150 ng/µl (Fig. 2B)  
that could then be used in immunisation experiments (Part III) and ELISA 
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assays (Fig. 2D, 2E, 3, 5).   
 Purified rSmTORed1 was functional in binding monoclonal anti-ed1   
(Fig. 2D) and did also bind C2 (Fig. 2E). We therefore screened by ELISA 
sera of S. mansoni infected patients and normal human sera for the presence 
of anti-rSmTORed1 antibodies (Fig. 3) and found 25 % of patients, but also   
10 % of uninfected individuals to be positive. Because the positive signal 
threshold of fold-increase values indicated was estimated arbitrarily, we 
wanted to ensure antibody specificity by competing real positive signals away 
by pre-incubation with soluble peptide. To this end we produced SmTORed1 
as a Halo-tagged fusion protein (Fig. 4). HALOed1 and the two control 
constructs could be purified from the soluble E. coli fraction were after 
immobilisation on magnetic beads and several washing steps readily used  
for different downstream applications. HALOed1 was specifically recognised 
by Western blot with monoclonal anti-ed1, but not HALO and HALOC4beta 
(Fig. 4C). 
 Sera of patients and uninfected humans that bound to rSmTORed1 (Fig. 
3) were pre-incubated either with HALO or HALOed1 on magnetic beads and 
ELISA was then performed with the sera depleted of specific antibodies by 
removal of the beads. With this assay, we were able to verity that the 
antibodies detected in 2 patients and 2 uninfected individuals were specific for 
immobilised antigen (Fig. 5). These individuals were the ones with the highest 
signal measured before (Fig. 3). This does not exclude, that some specific 
antibodies were present in others, but with this stringent method we are in the 
position to produce a convincing result. Healthy individuals displaying specific 
antibodies against rSmTORed1 might have been in contact with different bird 
schistosomes (belonging to the genus of Trichobilhariza in most of the cases). 
Trichobilharzia presumably die in the human skin after penetration of its non-
specific host thereby causing an inflammatory skin reaction also known as 
swimmer's itch (22).  
 SmTORed1 can be cleaved off the magnetic beads with TEV protease 
when produced as HALOed1, yielding a peptide with the SmTORed1 
sequence with only 6 residual N-terminally attached amino acids (Fig. 4A) 
instead of a His-tag and a 10 aa linker (Fig. 2A) as it is the case for 
rSmTORed1. Both peptides, rSmTORed1 and TEV protease cut SmTORed1 
 67	
  
were recognised by sera of mice immunised with rSmTORed1 (Fig. 6). Mouse 
Ig to rSmTORed1 did not cross-react with TEV cut rC4beta peptide sequence. 
No Ig bound on the immobilised inclusion body fraction indicating that a fairly 
clean preparation of rSmTORed1 had been used for immunisation.   
 In summary, we were able to produce purify functional recombinant 
SmTORed1 either as His-tagged protein, that was used for vaccination 
experiments (Part III), or Halo-tagged fusion protein. With this we were able to 
show that the long SmTORed1 loop containing the C2-binding motif of 
ShTORed1 also binds C2 (Fig. 1) and that some schistosomiasis patients and 
uninfected individuals have specific antibodies against rSmTORed1 (Fig. 5). 
SmTORed1 immunogenicity has been tested in mouse a murine vaccination 
model described below (Part III).  
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PART III: Recombinant SmTORed1 tested in a murine vaccination and 
challenge model confers protection against schistosomiasis    
 
Results published in: Clinical & Experimental Immunology, (2012), 170(3), 
342-357  
 
ABSTRACT 
 
 The search for a vaccine against schistosomiasis is a desirable goal, 
since there is currently only one chemotherapeutic available for the  
treatment of schistosomiasis. We had previously characterised SmTOR  
as an antigen expressed highest on the tegumental surface of S. mansoni 
cercariae. We tested its surface exposed extracellular loop 1, SmTORed1,  
as a potential vaccine candidate in the murine schistosomiasis model. 
Recombinant SmTORed1 was tested in two different mouse strains, BALB/c 
and C57BL/6, in the presence of either Complete/Incomplete Freund’s 
adjuvant (CFA/IFA) or muramyl dipeptide (MDP) as adjuvant. Only BALB/c 
mice receiving rSmTORed1 mixed with CFA/IFA generated significantly high 
specific antibody titers. Vaccination with rSmTORed1 induced a Th1-Type of 
immune response in BALB/c mice and was protective against parasite 
infection. A significant decrease in worm burden in the immunised animals 
versus the control groups was recorded. Thus, we consider rSmTORed1 to be 
an interesting anti-schistosome vaccine target to be followed up in additional 
experiments.  
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INTRODUCTION 
 
 Despite over a decade of research, praziquantel (PZQ) is the only 
chemotherapeutic available for treatment of schistosomiasis effective against 
all five schistosome species infecting humans (1). The concern about the 
emergence of developing drug resistance (2)  and the biphasic sensitivity of 
the parasite to the drug (3) with juvenile worm stages being insensitive to drug 
treatment (4), are reasons pushing the search for new compounds with 
schistosomicidal activity. But chemotherapy as such offers other additional 
disadvantages besides the development of drug resistance, such as the high 
costs generated and the lack of protection against re-infection after treatment 
(5). Consequently there is still plenty of reasons to aim for the development of 
a vaccine against schistosomiasis, although it has been stated already more 
than ten years ago to be difficult, but an achievable goal (6).  
 In the mid-1990ies, the WHO suggested six vaccine candidates to  
be tested independently for their efficacy against S. mansoni infection in a  
murine vaccination challenge model (7). Of those, Sm14 or Fatty Acid- 
Binding Protein (FABP) has clearly run the fastest through the vaccine 
development process involving important aspects of scale-up and industrial 
production and with Phase I and II clinical trials granted (8). In addition, there 
is a list of new proteins including those discovered with the help of proteomic 
analysis of the adult schistosome surface (9) and to which, amongst other 
membrane proteins (5), members of the so-called tetraspanin family belong 
to, four pass trans-membrane proteins whose extracellular loops have been 
shown to be protective against schistosome infection in the mouse when 
administered as recombinant vaccine in the case of TSP-1 and TSP-2 (10).  
 Obviously, the most interesting vaccine candidates are transmembrane 
proteins localised on the Schistosoma mansoni tegument due to their 
accessibility to the host immune response (11). Additionally, proteins highly 
expressed in the early intra-mammalian stages of S. mansoni like cercariae 
and schistosomulae are considered as interesting vaccine targets (12). 
 We tested a new vaccine candidate, the 111 amino acid long extra-
cellular loop one of SmTOR (SmTORed1), a membrane protein shown  
above to be expressed highest in S. mansoni cercariae (13). We did test  
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the recombinant peptide SmTORed1 in two different mouse strains, as 
suggested in standardised WHO vaccine trials before evaluating different 
candidate antigens for efficacy in a murine vaccination model (7) formu- 
lated either with Complete Freund's adjuvant (CFA) or with muramyl  
dipeptide (MDP) as an alternative. We did assess serum antibody levels to 
evaluate specific immune responses in the different experimental settings.  
We then performed an immunisation challenge experiment to see whether 
rSmTORed1 could interfere with S. mansoni infection in a mouse model.    
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MATERIALS AND METHODS  
 
Immunisation Procedure 
 
 Preliminary round: C57BL/6 and BALB/c mice (Harlan) were used first 
round of immunisation. 10 animals were immunised with antigen and the 
corresponding adjuvant, 5 mice in both of the two control groups were either 
immunised with inclusion bodies or 1 x PBS alone plus the corresponding 
adjuvant. Immunisation with antigen took place on day 0 followed by boost 
with antigen at days 21 and 42.  
 10 µg purified peptide in PBS was used per injection and animal, having 
10 animals in the immunised group. Inclusion bodies for injection of the first 
control group were generated from E. coli transfected with pET15b plasmid 
alone, purified over a Ni2+ as done for rSmTORed1 running the same FPLC 
program established for the peptide purification, followed by re-folding into 1 x 
PBS as described under Materials and Methods in Section II. As adjuvant, 
either CFA and ICF (Complete Freund’s adjuvant: first immunisation and 
Incomplete Freund’s adjuvant: boosting) or MDP (muramyl dipeptide: first 
immunisation and boosting) were used. Mice were injected subcutaneously in 
the neck fold.  
 Bleeding to monitor antibody response was performed at days -7, 14, 35 
and 63 via the tail vein (Fig. 1). Mice were terminated at day 63 and spleens 
were dissected for generation of spleen cell cultures.  
  
 The immunisation challenge experiment was performed using BALB/c 
mice (Charles River) in combination with CFA/IFA only. The experiment was 
performed with 10 animals in each group, receiving antigen, inclusion bodies 
or PBS mixed with adjuvant, as tested in the preliminary round. Challenge 
with infection took place at day 55 (13 days after the 2nd boost). Mice were 
infected subcutaneously with 150 S. mansoni cercariae via injection into the 
abdominal skin. At day 105 (7 weeks post infection) mice were sacrificed and 
parasite status was assessed by evaluation of the adult worm burden. Worms 
were dissected from the mesenteric veins and livers of the mice. Protection 
values were calculated as described elsewhere (14). The spleens were 
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removed in order to generate spleen cell cultures.  
 Serum samples to assess antibody response were taken at days -7, 14, 
35 as in the preliminary round (pre-challenge) and between days 105 and 107 
(post-challenge) (Fig. 1). 
 
Figure 1. Schedule murine vaccination and challenge model. Numbers 
indicate the days at which manipulations were done. Numbering starts at day 
0, at the time point of the first injection. Mice were boosted twice in 3 week 
intervals and bleeded at the days indicated.  
 
Mouse Serology  
 
 Mouse sera obtained at different time points were collected (Fig. 1) and 
specific antibody titers against rSmTORed1 were measured using an ELISA 
assay. For this, 96 well flat-bottom microtiter plates (Nunc) were coated     
overnight at 4 °C with 500 nmoles rSmTORed1 peptide per well in 100µl  
0.1 M carbonate bicarbonate buffer, pH 6.8. The plates were then blocked in            
1 x PBS containing 0.05 % Tween 20 (PBST)/ 5 % BSA for 1 h, 37 °C. Plates 
were washed 5 x with PBST between the different incubation steps. Serum 
samples were diluted in PBST at the appropriate dilution determined by serial 
dilutions for individual samples of each of the possible mouse strain adjuvant 
combinations and the different detection antibodies (described below), and 
100 µl were then added per well. Plates were incubated for 1 h at RT, and 
after washing the biotinylated primary antibody diluted in PBST was then 
added for another hour at RT. Bound antibody was detected with streptavidin-
HRP (Pierce) diluted 1:10'000 in PBS (30 min, RT) and the ELISA was 
developed by incubation with a TMB peroxidase substrate (BD Pharmigen). 
The absorbance was measured at 450 nm.          
 Biotinylated detection antibodies used were: Goat anti-mouse 
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IgG+IgM+IgA (ab6005, AbCam) and goat anti-mouse IgG (ab5868, AbCam) 
both diluted 1:10'000. Goat anti-mouse IgM (ab5929, AbCam) was diluted 
1:20'000. Serial dilutions were performed for the individual mouse strain 
adjuvant combinations as shown in Fig. 2 for BALB/c mice immunised with 
CFA/IFA. For Ig serology (IgG + IgM + IgA determination) sera of BALB/c 
CFA/IFA groups were diluted 1:25'600; C57BL/6 CFA/IFA sera were diluted 
1:6'400 and sera of MDP vaccinated mice were diluted 1:3'200 for BALB/c 
and C57BL/6 mice. For IgG and IgM determination in BALB/c CFA/IFA 
vaccinated mice, sera were diluted 1/12'800 or 1/3'200 respectively, as 
determined by endpoint titrations as well (data not shown).   
   
Spleen Cell Culture 
 
 Freshly removed spleen was cut into small pieces and the suspension 
pressed through a 70 µm nylon mesh (BD Falcon, #352350) into a 15 ml 
falcon tube containing RPMI medium supplemented with 5 % FCS 
(RPMI/FCS). Cells were pelleted, resuspended in 5 ml lysis buffer (0.15 M 
NH4Cl, 15 mM KHCO3, 0.1 mM Na2EDTA, pH 7.4) and incubated 5 min at  
RT. Cell lysis was stopped by adding 10 ml RPMI/FCS and centrifuged 
10 min, 200 x g at 4 °C. Cells were resuspended in complete medium 
(RPMI/FCS + 2 mM L-glutamine, 50 µM beta-mercaptoethanol, 100 U/ml 
Penicilin, 100 µg/ml streptomycin sulfate + 250 ng/ml amphotericin B + 
30 µg/ml polymyxin B) and cell number adjusted 1 x 107 cells per ml. Cells 
were cultured at 1 x 106 cells/ml in 200 µl in a 96-well tissue culture plate, 
either stimulated with 10 µg/ml rSmTORed1 or 5 µg/ml Concanavalin A. Cell 
culture supernatants were collected after 48 h of stimulation for IL-4 and TNFα 
analysis and after 72 h for IL-10 and INFγ. Mouse cytokine ELISA 
measurements were performed using ELISA Sets (BD OptiEATM).  
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RESULTS 
 
Immunisation with rSmTORed1 generates a humoral immune response in 
BALB/c and C57BL/6 mice  
 
 We immunised two different mouse strains with rSmTORed1 formulated 
with CFA/IFA or MDP as adjuvant according to the immunisation schedule in 
shown in Fig. 1. Serum samples were analysed before the injection and after 
the first boost in order to assess the amount of total Ig generated in the 
individual groups. Serial dilutions of individual sera of immunised versus 
control immunised animals (groups injected with adjuvant only) were tested 
for antibodies against rSmTORed1. Immunisation with CFA/IFA generated 
higher levels of anti-rSmTORed1 levels in C57BL/6 and BALB/c mice (Fig. 2), 
than immunisation with MDP. Therefore, these sera were subsequently 
analysed at higher dilutions. Specific antibodies in CFA/IFA BALB/c mice 
were detected at a dilution as high as 1:1'638'400 as compared to the control 
vaccinated mice (Fig. 2). MDP vaccinated mice did generate very low 
amounts of anti-rSmTORed1 Ig and sera were therefore tested at a low 
dilution, as determined experimentally (data not shown). 
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Figure 2. Endpoint titration of sera from four individual mice before (day -7, 
open symbols) and after (day 35, filled symbols) immunisation analysing anti-
rSmTORed1 Ig (IgG, IgM, IgA) responses. Data points are represented using 
triangles and dots for the three BALB/c mice immunised with antigen and 
CFA/IFA; values for the control mouse immunised with CFA/IFA/PBS only are 
shown as squares.   
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BALB/c but not C57BL/6 mice immunised with antigen in CFA/IFA generate 
significantly high antibody titers unlike the MDP immunised animals   
 
 After two injections with antigen and the corresponding adjuvant, mice of 
both strains immunised with CFA and boosted with IFA as well as BALB/c 
mice immunised with MDP showed a significant increase in Ig levels 
compared to levels in pre-immune sera (Fig. 3A and 3B, 3C). In C57BL/6 
mice immunised with MDP anti-rSmTORed1 Ig levels did not increase 
significantly (Fig. 3D). Yet, only BALB/c mice injected with antigen in CFA/IFA 
had significantly higher Ig levels at day 35 when compared to inclusion body 
(p = 0.0002) and PBS injected mice (p = 0.0002) at the same time point (Fig. 
3A). Sera were diluted 1:3'200 for Ig analysis of MDP vaccinated strains (Fig. 
3C and 3D) or 1:6'400 (Fig. 3B) and 1:25'600 (Fig. 3A) for CFA/IFA 
immunised mice. These dilutions were determined experimentally by titration 
of sera as shown in Fig. 2 and an appropriate dilution for screening of sera set 
according to OD values at 450 nm still within but near the boarder of the 
plateau reached at low serum dilutions. As per definition serum dilution is 
inversely correlated to the amount of antibody in a sample, low dilutions 
tested in MDP immunised mice and CFA/IFA immunised C57BL/6 mice reflect 
the relative weak immune response provoked (Fig. 3B, 3C and 3D) as 
compared to the one generated in BALB/c mice immunised with CFA/IFA (Fig. 
3A).   
 None of the control animals, both mice receiving inclusion bodies 
together with adjuvant and mice receiving adjuvant mixed with buffer only, did 
show an increase in anti-rSmTORed1 specific immune response.  
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Figure 3. Total Ig amounts in sera of individual mice immunised with 
rSmTORed1 (antigen, ag; n = 10) and the control groups injected  
with inclusion bodies (i. bodies; n = 5) or PBS (n = 5) monitored at day -7  
and day 35 of the trial. Sera for the ELISA assay were diluted 1:25'600  
(A), 1:6'400 (B) or 1:3'200 (C and D) as determined by endpoint titrations.  
Statistical analyses were performed with Student’s t-test: n.s. statistically not 
significant; statistically significant * (p < 0.05), ** (p < 0.01), *** (p < 0.001). 
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Peptide specific immune response can be boosted in BALB/c mice in every 
single animal, but not consistently in C57BL/6 mice 
 
 BALB/c mice responded to the second booster injection with peptide and 
IFA with a further increase in serum Ig to rSmTORed1 (Fig. 4A). Every single 
animal shows a slight increase of serum Ig, whereas the control Ig levels in 
the control animals do not increase markedly. This observation was not made 
in C57BL/6 mice. We didn't observe a uniform response to vaccination neither 
after the first nor after the second booster injection looking for anti-
rSmTORed1 Ig (Fig. 4B). 
 An increase in anti-SmTORed1 IgG (Fig. 5A) and IgM (Fig. 5B) subclass 
antibodies was detectable after the first and second booster of BALB/c with 
CFA/IFA.  
 
 
 
Figure 4. Ig (IgG, IgM, IgA) serology at days -7, 35 and 63 comparing (A) 
BALB/c with (B) C57BL/6 mice immunised with rSmTORed1 (antigen, ag; 
n = 10) or control groups immunised with inclusion bodies or buffer only (i. 
bodies and PBS; n = 5 or 2) using CFA/IFA as adjuvant. Sera for the ELISA 
assay were diluted 1:25'600 (A) or 1:6'400 (B). Arrows indicate injections at 
days 0 (prime), 21 (boost 1) and 42 (boost 2).    
 
 
 
 81	
  
 
 
Figure 5. (A) IgG serology and (B) IgM serology at days -7, 14 and 35 of 
BALB/c mice immunised with rSmTORed1 (antigen, ag; n = 3) using CFA/IFA 
as adjuvant; serum dilutions 1:12'800 for A and B. One representative sample 
of a PBS immunised mouse is shown as negative control for each isotype. 
Arrows indicate injections at days 0 (prime), 21 (boost 1) and 42 (boost 2).    
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rSmTORed1 CFA/IFA induced antibody response persists in BALB/c mice 
after challenge with S. mansoni infection  
 
 In an immunisation challenge experiment, we repeatedly observed an 
increase in peptide specific Ig when rSmTORed1 was administered together 
with CFA/IFA. Analysis of Ig response in mouse sera before the first boost 
(day 14) shows, that antibody titers only start to rise after applying the  
second dose of antigen (Fig. 6A). Antibodies generated against rSmTORed1 
persisted during the whole duration of the experiment and levels were not 
significantly altered in most of the animals after infection with S. mansoni 
cercariae (Fig. 6B). The infection itself did not lead to generation of anti-
rSmTORed1 antibodies, as no Ig was detectable in the two control groups.     
 
 
 
 
Figure 6. Ig (IgG, IgM, IgA) serology in mouse sera sampled at days -7, 14 
and 35 (A) or day 107 in addition (serum dilution 1:25'600). BALB/c mice were 
immunised with rSmTORed1 (antigen, ag) or control groups immunised with 
inclusion bodies (i.bodies) or buffer only (PBS) using CFA/IFA as adjuvant. All 
groups were infected with S. mansoni cercariae at day 55. Groups consisted 
of n=10 animals. Arrows indicate injections at days 0 (prime), 21 (boost 1) and 
42 (boost 2).    
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 Cytokine secretion of spleen cell cultures of immunised mice induced by 
rSmTORed1 does not differ in mice after immunisation and challenge 
   
 Spleen cell cultures of BALB/c mice immunised with rSmTORed1 in 
CFA/IFA (Fig. 7A) or mice immunised with peptide and then challenged by 
infection with S. mansoni cercariae (Fig. 7B) were tested for cytokine release 
upon stimulation with rSmTORed1. Spleen cell cultures of immunised animals 
performed 14 days after the second booster with antigen produced significant 
amounts of IFNγ and IL-10 when stimulated with rSmTORed1, as compared 
to the control spleen cell cultures originating from control vaccinated (PBS) 
animals (Fig. 7A). The IL-4 and TNFα levels after stimulation were not 
detectable. IFNγ, IL-10 and IL-4 but not TNFα were produced in all the spleen 
cell cultures tested when stimulated with Concanavalin A. This cytokine profile 
generated in immunised versus control animal spleen cell cultures after 
stimulation with purified antigen was not changed markedly after challenge 
with infection (Fig. 7B). The difference in the amount of cytokines detected 
was due to different experimental conditions, as verified by measuring an old 
reference sample together with the new samples. The infection itself does 
therefore not seem to alter the cytokine profile elicited by stimulation of the 
spleen cell cultures with rSmTORed1. We conclude, that vaccination with 
rSmTORed1 induces a Th1 type of immune response in mice that is not 
altered after infection.  
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Figure 7. Measurement of cytokines in the supernatant of spleen cell cultures 
after stimulation with rSmTORed1 (A) 14 days after the second boost or  
(B) after immunisation challenge experiment after 8 weeks (d 114) of 
infection. Number of spleens analysed: (A) n = 3/2 (rSmTORed1/PBS), (B)  
n = 2/2 (rSmTORed1/PBS). The bars represent the mean values ± S.D.  
of either 3 or 2 (rSmTORed1/PBS) different samples measured in triplicates 
each.  
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Vaccination of BALB/c with rSmTORed1 induces significant protection against 
challenge with S. mansoni cercariae  
 
 BALB/c mice were vaccinated with rSmTORed1, inclusion bodies or 
PBS only mixed with adjuvant (CFA/IFA) according to the immunisation 
schedule evaluated before (Fig. 1), challenged with infection by injection of S. 
mansoni cercariae and status of infection evaluated by analysing total worm 
burden after the whole duration of the experiment (7 weeks of infection). We 
found, that mice immunised with rSmTORed1 showed a significant reduction 
in worm burden when compared to both the control groups (Fig. 8). 
Vaccination resulted in 57 % reduction of worm burden when compared to the 
mice injected with the inclusion body fraction and a reduction of 62 % when 
compared to the PBS control mice. This difference could be due to fact that 
the inclusion body fraction might contain some impurities even after the 
sample cleanup by chromatography and dialysis that are able to slightly alter 
the immune response to infection in mice.   
 
 
 
Figure 8. Scattergram of total worm burden of BALB/c mice that were 
immunised with adjuvanted (CFA/IFA) rSmTORed1, inclusion bodies 
(i.bodies) or PBS and challenged with S. mansoni cercariae. The number of 
animals used per group was n = 10. Mean worm burden ± S.D.for the different 
groups were 27.8 ± 13.9 (PBS), 24.2 ± 17.4 (inclusion bodies) and 10.4 ± 8.6 
(rSmTORed1). Statistical analysis were performed using Student's t-test 
(unpaired): statistically significant * (p < 0.05), ** (p < 0.01).  
 86	
  
DISCUSSION 
 
 The overall humoral immune response against a peptide used for 
vaccination in a murine vaccination model depends on the intrinsic 
immunogenicity of the peptide, on the mouse strain and on the type of 
adjuvant used. We did evaluate that in our setting by measuring the amount of 
Ig generated against rSmTORed1. 
 BALB/c mice mounted a high response, when SmTOR extracellular 
domain 1 was produced as a recombinant peptide and was mixed with 
CFA/IFA for immunisation (Fig. 3A). Using the same adjuvant in C57BL/6 
mice generated a less high antibody titer, as sera were diluted 1:6'400 as 
compared to 1:1:25'600 for Ig detection (Fig. 3B). When injected with MDP, 
rSmTORed1 is little immunogenic both in BALB/c and C57BL/6 mice (Fig. 3C 
and D).   
 It is no big surprise that murmamyl dipeptide, an isolated cell wall 
component from M. tuberculosis targeting NOD-2 receptor (15) is not such a 
strong adjuvant as Complete Freund's adjuvant, a water in oil emulsion 
containing the whole inactivated mycobacterium (15). Furthermore, one can 
expect a differential innate immune response in the context of varying           
T-helper cell polarisation induced with regards to cytokine production, in two 
mouse strains with different genetic background and either prototypical Th1- 
(C57BL/6) or Th2- (BALB/c) type mouse strains (16). Schistosome infection 
indeed induces Th1 cytokines in C57BL/6 mice at the time of parasite 
residency in the lung and Th2 cytokines in BALB/c mice with however no 
measurable specific antibody production (17, 18). It has been shown that 
exogenous administration of IL-1 and IL-6 at the that time point had an effect 
on the specific antibody response against the parasite (adult worm tegumental 
antigen) with increased antibody levels in BALB/c mice associated with  
a significant reduction in worm burden, and promoting the opposite effect  
in C57BL/6 mice (17). This might partially explain the difference in 
responsiveness in terms of generation of a specific anti-SmTORed1 response 
upon vaccination with a strong pro-inflammatory response provoked by CFA 
in BALB/c and C57BL/6 mice, but also point to the fact that opposite effects in 
mice of different genetic background might be a confounding factor in 
 87	
  
immunisation challenge experiments. For example, immunisation with 
recombinant 3-P dehydrogenase emulsified in CFA protected BALB/c but not 
C57BL/6 mice from infection with S. mansoni (19).  
 The anti-rSmTORed1 immune response generated in BALB/c mice 
could be boosted with a third injection (Fig. 4A) and in these mice, specific 
IgG and IgM were measured in the context of a successful immunisation 
(Fig.5). Immunised BALB/c mice used for the infection model also generated 
antibody titers against rSmTORed1 (Fig. 6A), that did not vanish after the 
injection of cercariae in the context of the infection (Fig. 6B). The cytokine 
response in spleen cell cultures of immunised versus control mice, when 
these cells were stimulated with peptide, did not change if immunisation alone 
was performed (Fig. 7A) or after immunisation and infection of these mice 
(Fig. 7B). Immunised mice show protection against infection as compared to 
the two control groups, mice immunised with inclusion bodies or PBS together  
with adjuvant, apparent as a 57 % and 62 % reduction in worm burden 
respectively (Fig. 8). It is of major interest that infected mice without prior 
immunisation did not develop antibodies against SmTOR indicating that 
SmTOR is not recognised at the time of infection. This would explain, that few 
humans infected with schistosomes develop such antibodies as well. In 
addition, since our data indicate that SmTOR antibodies are protective, it goes 
without saying that the immunisation with this antigen might represent a real 
progress in the fight against schistosomes.  
 We assume, that the antibodies generated are protective against the 
infection, as an antigen expressed highest in the infectious larvae is targeted 
by those preventing the migration of the parasite to the lung and further on. 
Coating cercariae with host antibody might also prolong the dwell time in the 
skin, where it possibly can be attacked by host complement for a prolonged 
time period and binding of cytophilic antibodies might enhance the magnitude 
of the effect.     
 There are several examples of vaccine candidates that meet the target 
of a consistent induction of at least 40 % protection in the mouse model, as 
defined by the TDR/WHO program (7). Amongst those are original members 
of the six vaccine candidates proposed by the WHO to be tested 
independently by different labs (12) as well as new vaccine targets discovered 
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not least due to the various proteomic analysis of adult worm surface proteins 
(9, 20, 21). Recombinant Sm14 or FABP, a member of the "old guard" of 
vaccine candidates that induces high protection levels in Swiss outbred mice 
(22, 23), is now in the clinical trial phase (8). Old candidate number two 
mentioned here, Sm23 on the other hand did not confer protection as a 
recombinant protein (24), but only when delivered as DNA vaccine (25). Sm23 
is a member of the so-called tetraspanin family that are present on eukaryotic 
cells and are also abundant in the tegument of S. mansoni and promising 
vaccine candidates (11). Braschi et al. confirmed the presence of four 
members of tetraspanins on adult worm surface by proteomic analysis (20), 
all considered as new vaccine candidates. Besides the tetraspanins TSP-1 
and TSP-2, whose extracellular loops were tested in CBA mice (10) and 
showed a protective effect in this setting using a low responder mouse strain 
(26, 27), there are other membrane proteins tested in mouse. Sm29 (14), and 
most recently SmStoLP-2 (28), reduce worm burden by 51 % and 32 % after 
immunisation and infection of C57BL/6 mice respectively, both formulated 
with CFA/IFA. Both proteins are not only detectable in the tegument of adult 
worm, but more importantly also in skin-stage and lung-stage schistosomula  
(Sm29) and in 7-day old in vitro transformed schistosomula (SmStoLP-2) and 
therefore accessible as immune targets at an early time point after infection. It 
has been shown, that anti-rSmStoLP-2 antibodies could impair skin 
penetration of cercariae (28).  
 S. mansoni TOR is also a membrane bound antigen expressed highest 
even in the first intra-mammalian stage in the parasite cycle. Our work 
presented here shows, that its extracellular loop injected as recombinant 
protein protects BALB/c mice against infection with S. mansoni (Fig. 8). We 
therefore suggest to include rSmTORed1 as a member of potential vaccine 
candidates, that could be administered within a cocktail of antigens (29). 
Immunisation with a mixture of antigens tested and effective in different 
settings in mouse is most likely to do justice to the even bigger diversity in 
humans.          
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GENERAL DISCUSSION AND PERSPECTIVES 
 
  
 The genome of the flatworm Schistosoma mansoni has been sequenced 
completely (1). This remarkable achievement produced by genomics together 
with the flood of data generated by the various other "-omics" disciplines, that 
imply large-scale screens of the S. mansoni transcriptome, proteome and 
glycome (2, 3), pave the way for schistosomiasis vaccine research. However, 
high throughput approaches to identify new vaccine targets also offer 
disadvantages. In the case of proteomic studies, the detection limits of mass 
spectrometers also set a limit to the detection of low abundant proteins (4) 
only allowing detection of the most abundant and possibly least meaningful 
proteins (5). Proteins with no inferred functions will not be identified, if peptide 
searches are performed by using EST assemblies or gene prediction data 
based on the genome (3, 4). Previously, vaccine candidates were identified  
by the more classical method where highly immunogenic proteins were found 
by screening cDNA expression libraries (6) or whole protein extracts using 
sera from animals immunised with radiation-attenuated (RA) cercariae (7) and 
resistant versus susceptible infection sera from animal models or humans 
from endemic areas (5).  
 
The SmTOR Project  
 
 Schistosoma TOR had been identified by screening an S. haematobium 
adult worm cDNA library by phage display, using passively protective serum 
from vaccinated baboons (8). Based on the ShTOR cDNA sequence the 
receptor ORF sequence was also described for SmTOR (8). Both receptors 
were depicted as trispanning orphan receptors binding complement C2 and 
were also referred to as CRIT for complement C2 receptor inhibitor 
trispanning (9). We were therefore at the beginning of the project more 
interested in the role of SmTOR as a complement regulator rather than its 
immunogenicity in mice and humans.  We then observed, while trying to clone 
the full-length ORF from S. mansoni genomic DNA, that the SmTOR gene is 
not intronless as stated before (10) but contains three large introns, and that 
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the ORF reported originally was truncated at its 5' end. We were able  
to complete the molecular organisation of the SmTOR gene and report  
that SmTOR is a tetraspanning orphan receptor located on the tegument of 
S. mansoni cercariae and adult worm (11). We noticed in the first place,  
that its extracellular domain 1 containing the C2 binding motif (12) was 
predicted to not only consist of 27 amino acids, but instead to be a over 
hundred amino acid loop reinserting into the membrane with N-terminus, and 
secondly, that SmTOR is expressed highest in cercariae. We thus reasoned 
that SmTOR extracellular domain 1 (SmTORed1) might be an interesting  
new vaccine target.  
 
Recombinant SmTORed1 Vaccine Potential in the Murine Vaccination and 
Challenge Model  
  
 Regardless of the approach by which a putative vaccine candidate 
against schistosomiasis is identified, all vaccine candidates have to be 
expressed as proteins for testing of protection in an animal model (13).  
We consequently established the overexpression and purification of 
rSmTORed1 produced as His-tagged peptide in E. coli. In a first round, we 
tested the immunogenicity of purified rSmTORed1 in different mouse strains 
in combination with different adjuvants. As we saw, that highest specific 
antibody titers were generated in BALB/c mice immunised with antigen  
and CFA/IFA, we chose this mouse strain for the ensuing immunisation  
challenge experiment. We found the immunised mice to show 57 % and 62 % 
reduction in worm burden when compared to the inclusion bodies and  
PBS injected control groups. With this we demonstrated that rSmTOR is a 
potent vaccine in the murine schistosomiasis model.   
 We agree with others that it is unlikely that there is one magic bullet  
that can induce high levels of protection akin to the one provoked by 
immunisation with RA cercariae in the animal model (14, 15) and that a 
mixture of different peptides should be administered as antischistosomal 
vaccine (13). We wanted to evaluate in our work, if rSmTORed1 has the 
potential to induce protective immunity in the animal model and should be 
included in a list of antigens for a vaccine cocktail. Based on our preliminary 
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date we strongly suggest to do so, since rSmTORed1 in deed is an  
interesting vaccine candidate that confers significant resistance (57 - 62 %) 
against challenge infection. However, it is clear that the data produced in the 
murine schistosomiasis model cannot be extrapolated to the human  
condition (16). 
 Mice infected with laboratory strains of S. mansoni comprise of 
homogenous groups of animals with the same genetic background, 
challenged once with a defined S. mansoni isolate at an exactly defined dose 
after being immunised. Human schistosomiasis on the other hand affects  
a heterogeneous population, that most of the times gradually acquires 
schistosome infections of varying intensity (16). All these differences itemised 
contribute to the difficulty of the task to develop an effective vaccine against 
schistosomiasis. To date, there is no vaccine candidate against schistosome 
infection that is released for use in endemic areas (17). This situation will  
not change in the foreseeable future (18). 
 
SmTOR and Human Schistosomiasis 
 
 In human schistsosomiasis, it is of substantial interest to find markers for 
resistance and susceptibility to re-infection. These basically depend on the 
polarisation of the helper T cell subsets towards a Th1 or Th2 phenotype 
marking the type of Ig isotypes generated. This process depends amongst 
other things on the nature of antigen and the genetic composition of the 
individual (19). Whereas in most of the animal models a Th1 based 
mechanism seems to induce protection against schistosomes, the picture is 
not that clear in humans where acquired resistance can also correlate with the 
production of specific antibodies generated in a Th2 environment (20). No 
immune mechanism or specific antigens that are strongly associated with 
protection have been identified. An in vitro correlate study investigating 
cellular and humoral immune responses to S. mansoni vaccine candidate 
antigens in fact showed, that immune response profiles correlating with 
protection or susceptibility were unique for each molecule tested (20). That of 
course has an influence on the type of immune reaction one aims for 
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vaccination, since induction of the wrong or undesired immune response 
might lead to enhanced susceptibility or more serious pathology. The type of 
immune response generated can be modulated with different adjuvants. 
Unfortunately, the number of adjuvants allowed for use in humans is limited 
complicating the generation of the desired immune response upon 
vaccination.     
 Despite the fact, that two antigens when administered as a peptide 
vaccine require two completely different cytokine milieus in order to induce 
protection against infection, we attempt to speculate that in the case of 
rSmTORed1 the desirable antibody response in humans and mice might be 
the production of complement fixing antibodies. The presence or absence of 
ineffective and effective antibodies targeting the migrating larvae might be 
important (21). In deed, it has recently been shown for the two surface 
exposed proteins TSP-2 and SmStoLP-2, that show efficacy in the murine 
vaccination and challenge model, that putatively resistant individuals have 
high IgG1 and IgG3 titers against the recombinant antigen (22, 23).  
 In order to examine the occurrence of specific anti-SmTORed1 
antibodies, we were able to set up an ELISA measuring antibody response in 
infected versus non-infected humans. We found specific antibodies, as 
confirmed by a competition type ELISA performed with the Halo-tagged 
SmTORed1 domain, in a low percentage of infected and also in normal 
human sera. We did not expect the number of positive patients to be higher  
in infected individuals, because S. mansoni cercariae do not seem to die in  
the skin to such a high percentage that would make antigen available for  
the induction of an effective humoral immune response. The fact, that also  
uninfected individuals can have specific antibodies against rSmTORed1 we 
interpreted as such, that these individuals might have been in contact with 
bird schistosomes. Trichobilharzia is a member of the schistosome genera 
usually infecting birds.  
    It would of course be nice to get a grip on well-defined patient cohorts, 
both putatively resistant and susceptible with respect to S. mansoni infection 
or people with a history of Trichobilharzia infection. We could then evaluate,  
if the people that have antibodies against crude cercarial extract (24)  
also recognise rSmTORed1. That would hint towards the existence of a 
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SmTOR receptor homologue in Trichobilharzia. The mitochondrial genome  
of T. regenti has been sequenced (25), but not the whole genome. It would 
therefore require alternative approaches besides PCR amplification to even-
tually identify a new SmTOR receptor homologue in Trichobilharzia.   
 
Biological Activity of SmTOR 
 
 We have a strong interest to follow up on the biological function of 
SmTOR. We were able to show that rSmTORed1 also binds C2. We were so 
far not able to show the whole molecule to be functional on the cell surface. 
Several other complement regulators have been show to protect CHO cells 
bearing the receptor on its surface against complement attack (26-28). Up to 
date, we were not able to generate a CHO cell line that is overexpressing 
SmTOR on the cell surface. We moreover observed in transient transfectant, 
that the C-terminally GFP tagged receptor was not properly delivered to the 
cell surface membrane. This was also the case when transiently transfecting 
HeLa or HEK cells. We are still working on the SmTOR receptor 
overexpression in CHO cells, where we have a established an LDH release 
assay to measure complement mediated lysis. We want to see whether 
SmTOR overexpressing cells are less susceptible to complement attack than 
the wild type cell line.  
 Future plans include to identify possible new ligands, including the 
functional C2 analogue FB (29), of rSmTORed1 by receptor affinity 
chromatography and to eventually identify other biological functions of 
SmTORed1.  
 
 Taken together, we managed to newly characterise the S. mansoni TOR 
receptor and to show that it is a potential target for vaccination against 
schistosomiasis.  
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